A Phase 2/3 interventional study of Tofacitinib and Tofacitinib in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 104 sites in 19 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is one of 2 that started in 2013, is the only one in phase 2/3, and was the 6th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
This is a Phase 2/3, long term, open-label, follow-up study. Subjects will have previously participated in qualifying/index JIA studies of tofacitinib. Those who have already completed such participation and enroll outside the 14 day window following completion of the End of Study (EOS) Visit of the qualifying/index study will participate in a screening Visit to determine eligibility. A Baseline Visit will then occur within 28 days after the Screening Visit. For subjects who are completing participation in a qualifying study of tofacitinib and enrolling on the same day of the EOS Visit of the qualifying/index study, the EOS Visit of the qualifying/index study can be combined with the Screening and Baseline Visits for this study. The subjects who enroll within the 14 day window following completion of the EOS Visit of the qualifying/index study will participate in a combined Screening and Baseline Visit for this study. After the Baseline Visit, visits will occur at 1 month (1 month=30 days) and 3 months, then every 3 months thereafter as long as the subject remains in the study.
Approximately 340 participants are projected to enroll into this open label extension study after completing a qualifying/index study in the JIA program.
For subjects who entered this study from the A3921103 and A3921104 qualifying/index studies, their participation in this study ends after the first marketing approval of tofacitinib for the treatment of polyarticular course Juvenile Idiopathic Arthritis (pJIA) in any country. This study will end once the last subject, and all other subjects, who entered from index study A3921165 have completed approximately 1 year in this study, or after the first marketing approval of tofacitinib for the treatment of systemic JIA, whichever comes first.
The total duration of an individual subject's participation may vary depending upon when they enter the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infections:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be in tofacitinib treatment group.
Drug: Tofacitinib
Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165) 5 mg BID Dose Level: Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml) Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution. Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing.
Also known as: CP 690,550, Xeljanz
For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
Also known as: CP-690,550, Xeljanz
Number of Participants With Laboratory Test Abnormalities
Parameters: Hematology (hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, prothrombin international normalized ratio, erythrocyte sedimentation rate), clinical chemistry (bilirubin, direct/indirect bilirubin, aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high and low density lipoprotein cholesterol, Friedewald estimation, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, C reactive protein), urinalysis (specific gravity, potential of hydrogen (pH), glucose/ protein/ hemoglobin/ erythrocytes/ leukocytes, ketones, leukocyte esterase, hyaline casts, bacteria). Number of participants with at least 1 laboratory abnormality are reported.
Time frame: During study treatment (maximum up to 118 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily had a causal relationship with the treatment or usage. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that met one or more of the following criteria: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. An TEAE was any AE that occurred following the start of study treatment in this study or increased in severity following the start of study treatment in this study. AE included both SAEs and all non-SAEs.
Time frame: From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention)
Absolute Values of Body Weight at Baseline
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: At Baseline
Absolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 12
Absolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 24
Absolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 36
Absolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 48
Absolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 60
Absolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 72
Absolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 84
Absolute Value of Height at Baseline
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: At Baseline
Absolute Value of Height at Month 12 and Its Change From Baseline at Month 12
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 12
Absolute Value of Height at Month 24 and Its Change From Baseline at Month 24
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 24
Absolute Value of Height at Month 36 and Its Change From Baseline at Month 36
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 36
Absolute Value of Height at Month 48 and Its Change From Baseline at Month 48
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 48
Absolute Value of Height at Month 60 and Its Change From Baseline at Month 60
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 60
Absolute Value of Height at Month 72 and Its Change From Baseline at Month 72
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 72
Absolute Value of Height at Month 84 and Its Change From Baseline at Month 84
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
Time frame: Baseline, Month 84
Number of Participants According to Tanner Stage at Baseline
Pubertal development was measured using Tanner stage, by age group (2 to \<6 years, 6 to \<12 years, and 12 years or older) for males and females separately. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (fully developed breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes continue to enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size).
Time frame: At Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap)
Number of Participants With Shift in Tanner Stage From Baseline to Month 12
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 12. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 12
Number of Participants With Shift in Tanner Stage From Baseline to Month 24
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 24. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 24
Number of Participants With Shift in Tanner Stage From Baseline to Month 36
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 36. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 36
Number of Participants With Shift in Tanner Stage From Baseline to Month 48
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 48. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 48
Number of Participants With Shift in Tanner Stage From Baseline to Month 60
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 60. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 60
Number of Participants With Shift in Tanner Stage From Baseline to Month 72
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 72. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 72
Number of Participants With Shift in Tanner Stage From Baseline to Month 84
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 84. Only rows with non-zero values were reported in this outcome measure.
Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 84
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Systemic Juvenile Idiopathic Arthritis (sJIA) 1 Analysis Set
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a visual analogue scale (VAS). Higher scores signified more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity. In this outcome measure pJIA stands for polyarticular course juvenile idiopathic arthritis.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Enthesitis Related Arthritis (ERA) Analysis Set
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Psoriatic Arthritis (PsA) Analysis Set
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA American College of Rheumatology 30 (ACR 30) Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree Celsius(C) oral or \>38.6 degree C rectal on \>=2 consecutive days.
Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree C oral or \>38.6 degree C rectal on \>=2 consecutive days.
Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the standardization of uveitis nomenclature \[SUN\] working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1,3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA1 Analysis Set
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, methotrexate (MTX)/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA2 Analysis Set
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in pJIA Analysis Set
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in ERA Analysis Set
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in PsA Analysis Set
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.
Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Change From Baseline in Tender Entheseal Assessment at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Tender entheseal assessment was performed by the investigator as 'Yes' or 'No'. 'Yes' indicated the presence of tenderness upon firm palpation over the specified enthesis and 'No' indicated the absence of tenderness upon firm palpation over the indicated enthesis. A total of 16 entheseal sites were assessed and the number of tender sites was counted. The score ranges from 0 to 16, where 0 represents the best possible outcome (no tenderness) and 16 represents the worst possible outcome (maximum tenderness).
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Change From Baseline in Modified Schober's Test at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Modified Schober's test was performed at the study visits only in participants with enthesitis-related arthritis. With the participant standing erect and with feet together, a line joining the posterior superior iliac spines (the dimples of Venus) was used as a landmark for the lumbosacral junction. A mark was made 5 centimeters (cm) below and 10 cm above the lumbosacral junction. With the participant in maximum forward flexion with the knees straight, the investigator measures the distance between the two marks in centimeters. The full measurement between the two lines was recorded to the nearest tenth of a centimeter (e.g., 15.2 cm) on the appropriate CRF.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Change From Baseline in Overall Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Severity of overall back pain (at any time) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Change From Baseline in Nocturnal Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Severity of nocturnal back pain (at night) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Change From Baseline in Body Surface Area (BSA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set
BSA was measured as the percentage of BSA affected by psoriasis using the palm method; the participants palm was used for the calculation. One of the participant's palm to proximal interphalangeal (PIP) and thumb equals to 1% of BSA. Regions of the body included along with percentage of BSA: 1) head and neck = 10% (10 palms); 2) upper extremities = 20% (20 palms); 3) trunk (axillae and groin) = 30% (30 palms) and 4) lower extremities (buttocks) = 40% (40 palms).Total BSA was sum of all regions ranged from 0% to 100% (100 palms). The physician assessed the total BSA affected by psoriasis using the addition of the individual regions.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Change From Baseline in Physician's Global Assessment (PGA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set
PGA was used to determine participant's overall psoriasis lesions at a given time point. Overall lesions were graded for induration, erythema, and scaling based upon scales. Induration scale ranged from: 0 (no evidence of plaque elevation) to 5 (severe plaque elevation or more); erythema scale ranged from: 0 (no evidence of erythema, hyper pigmentation may be present) to 5 (dusky to deep red coloration); scaling scale ranged from: 0 (no evidence of scaling) to 5 (severe; very thick tenacious scale predominates). Total PGA score was calculated based on sum of 3 scales divided by 3 to obtain final PGA, ranging from 0 (no evidence) to 5 (maximum severity); higher scores indicated more severity of psoriasis.
Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
| Milestone | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Started | 302 |
| Completed | 175 |
| Not completed | 127 |
| Withdrew: Adverse event | 39 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Withdrawal by parent/guardian | 15 |
| Withdrew: Insufficient clinical response | 35 |
| Withdrew: Other | 11 |
Parameters: Hematology (hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, prothrombin international normalized ratio, erythrocyte sedimentation rate), clinical chemistry (bilirubin, direct/indirect bilirubin, aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high and low density lipoprotein cholesterol, Friedewald estimation, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, C reactive protein), urinalysis (specific gravity, potential of hydrogen (pH), glucose/ protein/ hemoglobin/ erythrocytes/ leukocytes, ketones, leukocyte esterase, hyaline casts, bacteria). Number of participants with at least 1 laboratory abnormality are reported.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Number of Participants With Laboratory Test Abnormalities | 294 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily had a causal relationship with the treatment or usage. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that met one or more of the following criteria: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. An TEAE was any AE that occurred following the start of study treatment in this study or increased in severity following the start of study treatment in this study. AE included both SAEs and all non-SAEs.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 268 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute Values of Body Weight at Baseline | 41.60 ± 19.35 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 12 | 49.16 ± 20.59 |
| Change at Month 12 | 6.52 ± 6.71 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 24 | 52.42 ± 20.15 |
| Change at Month 24 | 9.42 ± 8.08 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 36 | 56.96 ± 19.96 |
| Change at Month 36 | 12.44 ± 10.34 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 48 | 56.72 ± 17.69 |
| Change at Month 48 | 13.99 ± 11.06 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 60 | 58.07 ± 18.28 |
| Change at Month 60 | 17.50 ± 11.99 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 72 | 58.38 ± 19.40 |
| Change at Month 72 | 20.55 ± 13.49 |
Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Kilograms | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 84 | 59.31 ± 18.24 |
| Change at Month 84 | 23.80 ± 12.46 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute Value of Height at Baseline | 141.36 ± 23.62 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 12 | 147.87 ± 20.92 |
| Change at Month 12 | 5.55 ± 5.66 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 24 | 151.60 ± 19.34 |
| Change at Month 24 | 9.30 ± 7.96 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 36 | 155.76 ± 16.05 |
| Change at Month 36 | 10.97 ± 10.49 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 48 | 157.82 ± 14.81 |
| Change at Month 48 | 14.07 ± 12.55 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 60 | 158.92 ± 14.15 |
| Change at Month 60 | 17.71 ± 14.86 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 72 | 159.76 ± 14.41 |
| Change at Month 72 | 22.92 ± 16.35 |
Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Absolute at Month 84 | 163.15 ± 11.00 |
| Change at Month 84 | 27.95 ± 18.02 |
Pubertal development was measured using Tanner stage, by age group (2 to \<6 years, 6 to \<12 years, and 12 years or older) for males and females separately. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (fully developed breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes continue to enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size).
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male (2 to <6 Years): Pubic hair stage 1 | 12 |
| Male (2 to <6 Years): Genitalia stage 1 | 12 |
| Male (6 to <12 Years): Pubic hair stage 1 | 26 |
| Male (6 to <12 Years): Genitalia stage 1 | 26 |
| Male (6 to <12 Years): Pubic hair stage 2 | 3 |
| Male (6 to <12 Years): Genitalia stage 2 | 3 |
| Male (12 Years or older): Pubic hair stage 1 | 9 |
| Male (12 Years or older): Genitalia stage 1 | 6 |
| Male (12 Years or older): Pubic hair stage 2 | 6 |
| Male (12 Years or older): Genitalia stage 2 | 8 |
| Male (12 Years or older): Pubic hair stage 3 | 11 |
| Male (12 Years or older): Genitalia stage 3 | 14 |
| Male (12 Years or older): Pubic hair stage 4 | 14 |
| Male (12 Years or older): Genitalia stage 4 | 13 |
| Male (12 Years or older): Pubic hair stage 5 | 9 |
| Male (12 Years or older): Genitalia stage 5 | 8 |
| Female (2 to <6 Years): Pubic hair stage 1 | 8 |
| Female (2 to <6 Years): Breast exam stage 1 | 8 |
| Female (6 to <12 Years): Pubic hair stage 1 | 53 |
| Female (6 to <12 Years): Breast exam stage 1 | 47 |
| Female (6 to <12 Years): Pubic hair stage 2 | 4 |
| Female (6 to <12 Years): Breast exam stage 2 | 11 |
| Female (6 to <12 Years): Pubic hair stage 3 | 1 |
| Female (12 Years or older): Pubic hair stage 1 | 3 |
| Female (12 Years or older): Breast exam stage 1 | 1 |
| Female (12 Years or older): Pubic hair stage 2 | 14 |
| Female (12 Years or older): Breast exam stage 2 | 13 |
| Female (12 Years or older): Pubic hair stage 3 | 19 |
| Female (12 Years or older): Breast exam stage 3 | 27 |
| Female (12 Years or older): Pubic hair stage 4 | 34 |
| Female (12 Years or older): Breast exam stage 4 | 34 |
| Female (12 Years or older): Pubic hair stage 5 | 44 |
| Female (12 Years or older): Breast exam stage 5 | 39 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 12. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 11 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 11 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 18 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12) | 6 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12) | 2 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 12) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 17 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12) | 5 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12) | 2 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 1 (Month 12) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 12) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 12) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12) | 4 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12) | 8 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12) | 5 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12) | 7 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12) | 2 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 12) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12) | 2 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12) | 4 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 2 (Month 12) | 1 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12) | 2 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12) | 7 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12) | 2 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12) | 5 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12) | 6 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12) | 6 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 8 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 8 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 34 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12) | 11 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12) | 3 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 12) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 12) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 1 (Month 12) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 12) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12) | 30 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12) | 13 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12) | 3 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 1 (Month 12) | 2 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12) | 4 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 12) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 12) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12) | 5 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12) | 4 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12) | 6 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12) | 6 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12) | 5 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12) | 12 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12) | 18 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 1 (Month 12) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 4 (Month 12) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12) | 35 |
| Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12) | 3 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12) | 5 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12) | 3 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12) | 4 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12) | 12 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12) | 9 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 1 (Month 12) | 1 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12) | 9 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12) | 20 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 3 (Month 12) | 1 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12) | 33 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 24. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 7 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 7 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 8 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24) | 3 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 24) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 8 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 24) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 24) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 24) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24) | 4 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 24) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24) | 2 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24) | 3 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24) | 2 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24) | 2 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24) | 5 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24) | 4 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 8 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 8 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 15 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24) | 6 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24) | 4 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 24) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 3 (Baseline) to Stage 5 (Month 24) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24) | 13 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24) | 7 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24) | 5 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 24) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24) | 2 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 24) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24) | 5 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 24) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24) | 8 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 24) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24) | 4 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24) | 15 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 4 (Month 24) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24) | 24 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 24) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24) | 4 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 24) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24) | 5 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24) | 12 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24) | 6 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24) | 16 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24) | 21 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 36. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 3 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 3 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 5 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 3 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36) | 2 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 36) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36) | 4 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36) | 3 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 36) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36) | 3 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36) | 1 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36) | 4 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36) | 3 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 7 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 7 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 7 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36) | 6 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36) | 4 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 36) | 4 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 36) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 36) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36) | 8 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36) | 5 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36) | 5 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 36) | 2 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 36) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 36) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 36) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 36) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36) | 5 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36) | 8 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36) | 12 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36) | 24 |
| Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 36) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 36) | 3 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36) | 4 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36) | 12 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 36) | 1 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36) | 2 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36) | 16 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36) | 17 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 48. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 1 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48) | 3 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48) | 2 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48) | 2 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48) | 3 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48) | 3 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48) | 3 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48) | 2 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48) | 1 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48) | 2 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48) | 3 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 4 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 4 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48) | 4 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 48) | 6 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 48) | 3 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48) | 2 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 48) | 3 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48) | 5 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48) | 3 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 48) | 5 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 48) | 2 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 48) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 48) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48) | 5 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48) | 8 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48) | 17 |
| Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 48) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 48) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48) | 2 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48) | 3 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48) | 8 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 48) | 1 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48) | 8 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48) | 14 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 60. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60) | 1 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60) | 3 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60) | 3 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 60) | 2 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 60) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60) | 2 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 60) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60) | 1 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60) | 1 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60) | 2 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 1 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60) | 2 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 3 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 60) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 60) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60) | 2 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60) | 2 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60) | 3 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 60) | 2 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 60) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 60) | 6 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60) | 2 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60) | 9 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 60) | 1 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 60) | 6 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60) | 3 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60) | 8 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 72. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72) | 1 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 72) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72) | 2 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72) | 2 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72) | 1 |
| Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72) | 1 |
| Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72) | 2 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72) | 3 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72) | 3 |
| Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72) | 2 |
| Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72) | 3 |
| Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72) | 1 |
| Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72) | 2 |
Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 84. Only rows with non-zero values were reported in this outcome measure.
| Participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 3 (Month 84) | 1 |
| Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 84) | 1 |
| Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84) | 1 |
| Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 84) | 1 |
| Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 84) | 1 |
| Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 84) | 1 |
| Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 84) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 84) | 2 |
| Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 84) | 1 |
| Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 84) | 1 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 84) | 2 |
| Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84) | 1 |
| Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 84) | 1 |
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a visual analogue scale (VAS). Higher scores signified more disease activity.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.44 ± 2.70 |
| Change at Month 3 | -4.95 ± 2.63 |
| Change at Month 6 | -5.33 ± 2.44 |
| Change at Month 9 | -5.02 ± 2.59 |
| Change at Month 12 | -5.13 ± 2.30 |
| Change at Month 15 | -4.49 ± 2.55 |
| Change at Month 18 | -4.82 ± 2.81 |
| Change at Month 21 | -4.84 ± 2.41 |
| Change at Month 24 | -4.80 ± 2.38 |
| Change at Month 27 | -5.00 ± 2.45 |
| Change at Month 30 | -5.59 ± 2.13 |
| Change at Month 33 | -5.42 ± 2.16 |
| Change at Month 36 | -5.72 ± 2.39 |
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.56 ± 2.66 |
| Change at Month 3 | -5.07 ± 2.50 |
| Change at Month 6 | -5.24 ± 2.48 |
| Change at Month 9 | -5.01 ± 2.63 |
| Change at Month 12 | -4.98 ± 2.33 |
| Change at Month 15 | -4.39 ± 2.54 |
| Change at Month 18 | -4.83 ± 2.81 |
| Change at Month 21 | -4.76 ± 2.40 |
| Change at Month 24 | -4.67 ± 2.36 |
| Change at Month 27 | -4.74 ± 2.39 |
| Change at Month 30 | -5.77 ± 2.13 |
| Change at Month 33 | -5.38 ± 2.46 |
| Change at Month 36 | -4.90 ± 2.77 |
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity. In this outcome measure pJIA stands for polyarticular course juvenile idiopathic arthritis.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.24 ± 2.29 |
| Change at Month 3 | -4.71 ± 2.14 |
| Change at Month 6 | -4.79 ± 2.14 |
| Change at Month 9 | -4.94 ± 2.07 |
| Change at Month 12 | -4.98 ± 2.22 |
| Change at Month 15 | -5.20 ± 2.16 |
| Change at Month 18 | -5.20 ± 2.17 |
| Change at Month 21 | -5.14 ± 2.26 |
| Change at Month 24 | -5.27 ± 2.07 |
| Change at Month 27 | -5.23 ± 2.02 |
| Change at Month 30 | -5.24 ± 2.05 |
| Change at Month 33 | -5.40 ± 2.00 |
| Change at Month 36 | -5.50 ± 2.00 |
| Change at Month 39 | -5.41 ± 2.19 |
| Change at Month 42 | -5.59 ± 2.03 |
| Change at Month 45 | -5.63 ± 1.98 |
| Change at Month 48 | -5.86 ± 1.82 |
| Change at Month 51 | -5.77 ± 1.89 |
| Change at Month 54 | -5.91 ± 1.63 |
| Change at Month 57 | -5.90 ± 1.78 |
| Change at Month 60 | -5.82 ± 1.91 |
| Change at Month 63 | -6.05 ± 1.82 |
| Change at Month 66 | -5.71 ± 2.04 |
| Change at Month 69 | -5.91 ± 1.79 |
| Change at Month 72 | -5.91 ± 1.85 |
| Change at Month 75 | -5.93 ± 1.84 |
| Change at Month 78 | -6.23 ± 1.75 |
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.00 ± 1.72 |
| Change at Month 3 | -3.76 ± 1.59 |
| Change at Month 6 | -3.37 ± 1.80 |
| Change at Month 9 | -4.13 ± 1.43 |
| Change at Month 12 | -3.80 ± 1.57 |
| Change at Month 15 | -3.96 ± 1.66 |
| Change at Month 18 | -4.33 ± 1.29 |
| Change at Month 21 | -4.58 ± 1.06 |
| Change at Month 24 | -4.23 ± 1.72 |
| Change at Month 27 | -4.13 ± 1.30 |
| Change at Month 30 | -4.27 ± 1.37 |
| Change at Month 33 | -4.25 ± 1.36 |
| Change at Month 36 | -4.17 ± 1.42 |
Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.18 ± 2.36 |
| Change at Month 3 | -4.36 ± 2.15 |
| Change at Month 6 | -4.84 ± 1.89 |
| Change at Month 9 | -5.00 ± 1.87 |
| Change at Month 12 | -4.75 ± 1.96 |
| Change at Month 15 | -4.70 ± 2.09 |
| Change at Month 18 | -4.69 ± 1.89 |
| Change at Month 21 | -4.69 ± 2.01 |
| Change at Month 24 | -4.95 ± 2.45 |
| Change at Month 27 | -4.96 ± 2.10 |
| Change at Month 30 | -4.62 ± 2.07 |
| Change at Month 33 | -4.83 ± 2.07 |
| Change at Month 36 | -4.39 ± 2.09 |
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
| Joints With Active Arthritis | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -7.31 ± 7.40 |
| Change at Month 3 | -7.65 ± 8.15 |
| Change at Month 6 | -8.69 ± 7.68 |
| Change at Month 9 | -8.65 ± 7.48 |
| Change at Month 12 | -10.15 ± 8.39 |
| Change at Month 15 | -9.08 ± 7.45 |
| Change at Month 18 | -9.31 ± 7.43 |
| Change at Month 21 | -10.45 ± 8.13 |
| Change at Month 24 | -10.44 ± 8.20 |
| Change at Month 27 | -10.38 ± 8.45 |
| Change at Month 30 | -10.47 ± 8.24 |
| Change at Month 33 | -11.42 ± 8.45 |
| Change at Month 36 | -11.33 ± 8.60 |
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
| Joints With Active Arthritis | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -7.03 ± 7.34 |
| Change at Month 3 | -7.68 ± 7.82 |
| Change at Month 6 | -8.28 ± 7.68 |
| Change at Month 9 | -8.33 ± 7.44 |
| Change at Month 12 | -9.72 ± 8.50 |
| Change at Month 15 | -8.53 ± 7.34 |
| Change at Month 18 | -8.72 ± 7.27 |
| Change at Month 21 | -9.43 ± 8.08 |
| Change at Month 24 | -9.67 ± 8.11 |
| Change at Month 27 | -9.42 ± 8.18 |
| Change at Month 30 | -9.38 ± 8.24 |
| Change at Month 33 | -9.88 ± 8.31 |
| Change at Month 36 | -7.60 ± 7.57 |
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
| Joints With Active Arthritis | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -9.64 ± 7.24 |
| Change at Month 3 | -10.36 ± 7.56 |
| Change at Month 6 | -10.44 ± 6.91 |
| Change at Month 9 | -10.45 ± 7.00 |
| Change at Month 12 | -10.98 ± 7.10 |
| Change at Month 15 | -10.87 ± 6.54 |
| Change at Month 18 | -11.19 ± 7.67 |
| Change at Month 21 | -11.39 ± 7.35 |
| Change at Month 24 | -11.31 ± 6.83 |
| Change at Month 27 | -11.22 ± 6.70 |
| Change at Month 30 | -11.25 ± 7.40 |
| Change at Month 33 | -11.72 ± 7.35 |
| Change at Month 36 | -11.57 ± 7.54 |
| Change at Month 39 | -11.36 ± 7.21 |
| Change at Month 42 | -11.25 ± 7.14 |
| Change at Month 45 | -11.24 ± 7.76 |
| Change at Month 48 | -11.38 ± 7.04 |
| Change at Month 51 | -11.03 ± 7.18 |
| Change at Month 54 | -10.92 ± 5.98 |
| Change at Month 57 | -10.55 ± 6.00 |
| Change at Month 60 | -9.96 ± 5.14 |
| Change at Month 63 | -10.35 ± 6.28 |
| Change at Month 66 | -9.95 ± 5.46 |
| Change at Month 69 | -10.68 ± 6.02 |
| Change at Month 72 | -10.49 ± 6.06 |
| Change at Month 75 | -10.50 ± 6.03 |
| Change at Month 78 | -10.30 ± 5.74 |
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
| Joints With Active Arthritis | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -6.71 ± 3.85 |
| Change at Month 3 | -6.24 ± 3.13 |
| Change at Month 6 | -6.16 ± 3.53 |
| Change at Month 9 | -6.87 ± 2.97 |
| Change at Month 12 | -7.07 ± 3.37 |
| Change at Month 15 | -7.54 ± 2.57 |
| Change at Month 18 | -7.67 ± 3.39 |
| Change at Month 21 | -7.75 ± 3.25 |
| Change at Month 24 | -6.82 ± 4.62 |
| Change at Month 27 | -7.25 ± 3.39 |
| Change at Month 30 | -7.45 ± 2.91 |
| Change at Month 33 | -7.33 ± 3.73 |
| Change at Month 36 | -7.17 ± 3.71 |
Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.
| Joints With Active Arthritis | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -8.68 ± 6.82 |
| Change at Month 3 | -9.28 ± 6.23 |
| Change at Month 6 | -9.94 ± 6.51 |
| Change at Month 9 | -10.00 ± 6.49 |
| Change at Month 12 | -9.75 ± 6.75 |
| Change at Month 15 | -9.93 ± 7.12 |
| Change at Month 18 | -10.54 ± 7.53 |
| Change at Month 21 | -10.92 ± 7.16 |
| Change at Month 24 | -10.73 ± 6.00 |
| Change at Month 27 | -11.33 ± 7.54 |
| Change at Month 30 | -10.54 ± 7.83 |
| Change at Month 33 | -10.92 ± 7.84 |
| Change at Month 36 | -9.11 ± 8.13 |
| Joints With Limitation of Motion | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -3.60 ± 5.69 |
| Change at Month 3 | -3.85 ± 5.61 |
| Change at Month 6 | -4.21 ± 6.47 |
| Change at Month 9 | -4.40 ± 5.80 |
| Change at Month 12 | -5.02 ± 6.04 |
| Change at Month 15 | -5.50 ± 7.06 |
| Change at Month 18 | -5.08 ± 6.31 |
| Change at Month 21 | -5.38 ± 7.08 |
| Change at Month 24 | -5.67 ± 7.04 |
| Change at Month 27 | -5.75 ± 7.50 |
| Change at Month 30 | -4.53 ± 6.78 |
| Change at Month 33 | -3.67 ± 5.73 |
| Change at Month 36 | -4.67 ± 6.18 |
| Joints With Limitation of Motion | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -3.26 ± 5.45 |
| Change at Month 3 | -3.50 ± 5.47 |
| Change at Month 6 | -3.65 ± 5.99 |
| Change at Month 9 | -3.99 ± 5.65 |
| Change at Month 12 | -4.68 ± 5.93 |
| Change at Month 15 | -4.78 ± 6.66 |
| Change at Month 18 | -4.44 ± 6.02 |
| Change at Month 21 | -4.52 ± 7.06 |
| Change at Month 24 | -4.81 ± 7.05 |
| Change at Month 27 | -5.16 ± 7.44 |
| Change at Month 30 | -3.54 ± 6.53 |
| Change at Month 33 | -1.63 ± 3.58 |
| Change at Month 36 | -1.20 ± 2.17 |
| Joints With Limitation of Motion | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -5.48 ± 5.99 |
| Change at Month 3 | -5.97 ± 5.96 |
| Change at Month 6 | -6.13 ± 6.41 |
| Change at Month 9 | -6.25 ± 6.38 |
| Change at Month 12 | -6.22 ± 6.29 |
| Change at Month 15 | -6.72 ± 6.76 |
| Change at Month 18 | -6.61 ± 6.61 |
| Change at Month 21 | -6.59 ± 6.59 |
| Change at Month 24 | -6.71 ± 6.22 |
| Change at Month 27 | -6.59 ± 6.18 |
| Change at Month 30 | -6.71 ± 7.13 |
| Change at Month 33 | -6.69 ± 6.63 |
| Change at Month 36 | -7.09 ± 6.72 |
| Change at Month 39 | -7.13 ± 6.72 |
| Change at Month 42 | -6.80 ± 6.67 |
| Change at Month 45 | -7.13 ± 6.38 |
| Change at Month 48 | -7.20 ± 6.16 |
| Change at Month 51 | -7.42 ± 7.05 |
| Change at Month 54 | -6.69 ± 5.37 |
| Change at Month 57 | -6.53 ± 6.21 |
| Change at Month 60 | -6.31 ± 5.13 |
| Change at Month 63 | -6.70 ± 6.54 |
| Change at Month 66 | -6.33 ± 5.42 |
| Change at Month 69 | -7.00 ± 6.51 |
| Change at Month 72 | -7.16 ± 6.68 |
| Change at Month 75 | -7.20 ± 6.47 |
| Change at Month 78 | -7.21 ± 5.58 |
| Joints With Limitation of Motion | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.48 ± 3.44 |
| Change at Month 3 | -4.29 ± 4.48 |
| Change at Month 6 | -4.00 ± 5.66 |
| Change at Month 9 | -5.13 ± 4.70 |
| Change at Month 12 | -5.53 ± 5.00 |
| Change at Month 15 | -6.08 ± 5.38 |
| Change at Month 18 | -5.50 ± 5.18 |
| Change at Month 21 | -5.42 ± 4.98 |
| Change at Month 24 | -4.82 ± 6.00 |
| Change at Month 27 | -5.08 ± 5.02 |
| Change at Month 30 | -5.55 ± 5.13 |
| Change at Month 33 | -4.58 ± 2.87 |
| Change at Month 36 | -4.58 ± 4.01 |
| Joints With Limitation of Motion | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -5.00 ± 4.83 |
| Change at Month 3 | -5.06 ± 4.82 |
| Change at Month 6 | -5.63 ± 5.11 |
| Change at Month 9 | -5.50 ± 4.77 |
| Change at Month 12 | -4.88 ± 4.41 |
| Change at Month 15 | -5.07 ± 4.85 |
| Change at Month 18 | -4.85 ± 5.34 |
| Change at Month 21 | -5.00 ± 5.24 |
| Change at Month 24 | -5.27 ± 4.36 |
| Change at Month 27 | -5.50 ± 5.30 |
| Change at Month 30 | -5.31 ± 5.51 |
| Change at Month 33 | -5.42 ± 5.95 |
| Change at Month 36 | -3.78 ± 5.47 |
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
| milligrams per deciliter (mg/dL) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -2.29 ± 4.58 |
| Change at Month 3 | -2.43 ± 4.63 |
| Change at Month 6 | -2.67 ± 4.16 |
| Change at Month 9 | -2.22 ± 4.47 |
| Change at Month 12 | -2.25 ± 5.43 |
| Change at Month 15 | -2.50 ± 4.02 |
| Change at Month 18 | -2.09 ± 4.34 |
| Change at Month 21 | -3.01 ± 3.49 |
| Change at Month 24 | -2.71 ± 3.26 |
| Change at Month 27 | -1.78 ± 4.23 |
| Change at Month 30 | -2.46 ± 3.58 |
| Change at Month 33 | -1.57 ± 1.80 |
| Change at Month 36 | -0.88 ± 1.50 |
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
| milligrams per deciliter (mg/dL) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -2.50 ± 4.86 |
| Change at Month 3 | -2.76 ± 4.81 |
| Change at Month 6 | -2.84 ± 4.32 |
| Change at Month 9 | -2.33 ± 4.68 |
| Change at Month 12 | -2.34 ± 5.75 |
| Change at Month 15 | -2.87 ± 4.23 |
| Change at Month 18 | -2.47 ± 4.56 |
| Change at Month 21 | -3.44 ± 3.77 |
| Change at Month 24 | -3.13 ± 3.55 |
| Change at Month 27 | -2.24 ± 4.56 |
| Change at Month 30 | -3.01 ± 3.80 |
| Change at Month 33 | -1.64 ± 1.99 |
| Change at Month 36 | -0.70 ± 1.42 |
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
| milligrams per deciliter (mg/dL) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.78 ± 1.97 |
| Change at Month 3 | -0.71 ± 2.08 |
| Change at Month 6 | -0.79 ± 2.07 |
| Change at Month 9 | -0.77 ± 2.17 |
| Change at Month 12 | -0.71 ± 2.01 |
| Change at Month 15 | -0.71 ± 2.41 |
| Change at Month 18 | -0.65 ± 2.16 |
| Change at Month 21 | -0.77 ± 2.17 |
| Change at Month 24 | -0.91 ± 2.16 |
| Change at Month 27 | -0.46 ± 3.78 |
| Change at Month 30 | -0.86 ± 2.18 |
| Change at Month 33 | -0.90 ± 2.21 |
| Change at Month 36 | -0.85 ± 2.21 |
| Change at Month 39 | -0.86 ± 2.27 |
| Change at Month 42 | -0.92 ± 2.21 |
| Change at Month 45 | -0.83 ± 2.17 |
| Change at Month 48 | -1.04 ± 2.49 |
| Change at Month 51 | -0.96 ± 2.52 |
| Change at Month 54 | -0.81 ± 2.83 |
| Change at Month 57 | -0.93 ± 2.61 |
| Change at Month 60 | -0.57 ± 1.20 |
| Change at Month 63 | -0.60 ± 1.96 |
| Change at Month 66 | -0.35 ± 2.55 |
| Change at Month 69 | -0.69 ± 1.80 |
| Change at Month 72 | -0.30 ± 3.05 |
| Change at Month 75 | -0.29 ± 1.70 |
| Change at Month 78 | -0.70 ± 1.14 |
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
| milligrams per deciliter (mg/dL) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.09 ± 0.88 |
| Change at Month 3 | -0.07 ± 0.84 |
| Change at Month 6 | -0.09 ± 0.85 |
| Change at Month 9 | 0.01 ± 0.65 |
| Change at Month 12 | 0.19 ± 0.90 |
| Change at Month 15 | 0.08 ± 0.51 |
| Change at Month 18 | -0.05 ± 0.33 |
| Change at Month 21 | -0.08 ± 0.25 |
| Change at Month 24 | 0.06 ± 0.35 |
| Change at Month 27 | -0.04 ± 0.35 |
| Change at Month 30 | -0.09 ± 0.21 |
| Change at Month 33 | -0.07 ± 0.24 |
| Change at Month 36 | -0.05 ± 0.19 |
CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.
| milligrams per deciliter (mg/dL) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.37 ± 1.50 |
| Change at Month 3 | -0.63 ± 1.58 |
| Change at Month 6 | -0.66 ± 1.54 |
| Change at Month 9 | -0.64 ± 1.49 |
| Change at Month 12 | -0.64 ± 1.50 |
| Change at Month 15 | -0.32 ± 1.81 |
| Change at Month 18 | 0.79 ± 5.73 |
| Change at Month 21 | -0.62 ± 1.54 |
| Change at Month 24 | -0.61 ± 1.51 |
| Change at Month 27 | -0.36 ± 2.14 |
| Change at Month 30 | -0.51 ± 0.96 |
| Change at Month 33 | -0.63 ± 1.82 |
| Change at Month 36 | -0.92 ± 1.74 |
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
| millimeters per hour (mm/hr) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -28.69 ± 29.50 |
| Change at Month 3 | -32.32 ± 30.44 |
| Change at Month 6 | -34.61 ± 27.26 |
| Change at Month 9 | -29.47 ± 30.87 |
| Change at Month 12 | -27.54 ± 35.19 |
| Change at Month 15 | -25.53 ± 35.89 |
| Change at Month 18 | -23.63 ± 34.29 |
| Change at Month 21 | -27.10 ± 29.10 |
| Change at Month 24 | -29.07 ± 30.61 |
| Change at Month 27 | -20.25 ± 27.77 |
| Change at Month 30 | -21.88 ± 26.15 |
| Change at Month 33 | -14.33 ± 22.44 |
| Change at Month 36 | -8.89 ± 19.80 |
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
| millimeters per hour (mm/hr) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -30.49 ± 29.84 |
| Change at Month 3 | -34.05 ± 30.25 |
| Change at Month 6 | -36.21 ± 26.24 |
| Change at Month 9 | -30.55 ± 30.45 |
| Change at Month 12 | -29.17 ± 33.37 |
| Change at Month 15 | -26.74 ± 36.37 |
| Change at Month 18 | -25.55 ± 35.04 |
| Change at Month 21 | -29.00 ± 27.65 |
| Change at Month 24 | -30.38 ± 29.67 |
| Change at Month 27 | -20.42 ± 26.62 |
| Change at Month 30 | -27.31 ± 25.43 |
| Change at Month 33 | -22.25 ± 18.71 |
| Change at Month 36 | -8.80 ± 26.41 |
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
| millimeters per hour (mm/hr) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -10.48 ± 21.15 |
| Change at Month 3 | -10.52 ± 24.64 |
| Change at Month 6 | -10.01 ± 23.81 |
| Change at Month 9 | -11.31 ± 23.06 |
| Change at Month 12 | -8.75 ± 23.64 |
| Change at Month 15 | -11.53 ± 23.75 |
| Change at Month 18 | -10.09 ± 23.56 |
| Change at Month 21 | -10.80 ± 23.95 |
| Change at Month 24 | -10.87 ± 25.27 |
| Change at Month 27 | -9.96 ± 24.00 |
| Change at Month 30 | -8.82 ± 24.92 |
| Change at Month 33 | -9.69 ± 22.09 |
| Change at Month 36 | -8.13 ± 22.82 |
| Change at Month 39 | -7.54 ± 22.93 |
| Change at Month 42 | -8.74 ± 22.91 |
| Change at Month 45 | -8.78 ± 20.76 |
| Change at Month 48 | -9.15 ± 24.99 |
| Change at Month 51 | -8.83 ± 22.74 |
| Change at Month 54 | -10.05 ± 24.80 |
| Change at Month 57 | -7.87 ± 24.53 |
| Change at Month 60 | -3.13 ± 24.64 |
| Change at Month 63 | -5.30 ± 22.11 |
| Change at Month 66 | -4.16 ± 22.98 |
| Change at Month 69 | -7.22 ± 18.11 |
| Change at Month 72 | -7.77 ± 18.49 |
| Change at Month 75 | -4.04 ± 24.52 |
| Change at Month 78 | -8.87 ± 18.67 |
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
| millimeters per hour (mm/hr) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -5.74 ± 22.70 |
| Change at Month 3 | -6.84 ± 22.73 |
| Change at Month 6 | -5.89 ± 23.81 |
| Change at Month 9 | -3.53 ± 13.69 |
| Change at Month 12 | -0.87 ± 16.34 |
| Change at Month 15 | -3.31 ± 18.30 |
| Change at Month 18 | -8.42 ± 15.37 |
| Change at Month 21 | -7.42 ± 15.49 |
| Change at Month 24 | -3.92 ± 15.96 |
| Change at Month 27 | -2.64 ± 29.16 |
| Change at Month 30 | -7.55 ± 13.52 |
| Change at Month 33 | -5.75 ± 13.84 |
| Change at Month 36 | -6.00 ± 12.65 |
ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.
| millimeters per hour (mm/hr) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -10.00 ± 21.55 |
| Change at Month 3 | -9.33 ± 27.47 |
| Change at Month 6 | -12.27 ± 23.62 |
| Change at Month 9 | -12.60 ± 24.47 |
| Change at Month 12 | -12.13 ± 22.19 |
| Change at Month 15 | -8.67 ± 23.58 |
| Change at Month 18 | -7.36 ± 27.03 |
| Change at Month 21 | -10.67 ± 21.12 |
| Change at Month 24 | -6.82 ± 15.91 |
| Change at Month 27 | -7.33 ± 16.91 |
| Change at Month 30 | -4.31 ± 23.33 |
| Change at Month 33 | -10.36 ± 27.93 |
| Change at Month 36 | -8.00 ± 25.22 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.87 ± 0.75 |
| Change at Month 3 | -0.90 ± 0.72 |
| Change at Month 6 | -0.96 ± 0.71 |
| Change at Month 9 | -1.00 ± 0.71 |
| Change at Month 12 | -0.83 ± 0.69 |
| Change at Month 15 | -0.86 ± 0.70 |
| Change at Month 18 | -0.81 ± 0.66 |
| Change at Month 21 | -0.98 ± 0.66 |
| Change at Month 24 | -1.04 ± 0.66 |
| Change at Month 27 | -1.04 ± 0.74 |
| Change at Month 30 | -1.13 ± 0.81 |
| Change at Month 33 | -1.00 ± 0.92 |
| Change at Month 36 | -1.07 ± 0.73 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.89 ± 0.77 |
| Change at Month 3 | -0.94 ± 0.73 |
| Change at Month 6 | -0.96 ± 0.72 |
| Change at Month 9 | -1.01 ± 0.71 |
| Change at Month 12 | -0.85 ± 0.67 |
| Change at Month 15 | -0.85 ± 0.68 |
| Change at Month 18 | -0.83 ± 0.59 |
| Change at Month 21 | -0.98 ± 0.64 |
| Change at Month 24 | -1.07 ± 0.65 |
| Change at Month 27 | -1.03 ± 0.71 |
| Change at Month 30 | -1.12 ± 0.76 |
| Change at Month 33 | -0.89 ± 0.89 |
| Change at Month 36 | -0.95 ± 0.66 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.52 ± 0.51 |
| Change at Month 3 | -0.52 ± 0.54 |
| Change at Month 6 | -0.59 ± 0.57 |
| Change at Month 9 | -0.63 ± 0.61 |
| Change at Month 12 | -0.65 ± 0.62 |
| Change at Month 15 | -0.71 ± 0.63 |
| Change at Month 18 | -0.70 ± 0.65 |
| Change at Month 21 | -0.72 ± 0.65 |
| Change at Month 24 | -0.73 ± 0.66 |
| Change at Month 27 | -0.73 ± 0.68 |
| Change at Month 30 | -0.71 ± 0.64 |
| Change at Month 33 | -0.74 ± 0.73 |
| Change at Month 36 | -0.75 ± 0.72 |
| Change at Month 39 | -0.75 ± 0.73 |
| Change at Month 42 | -0.75 ± 0.74 |
| Change at Month 45 | -0.74 ± 0.73 |
| Change at Month 48 | -0.80 ± 0.72 |
| Change at Month 51 | -0.78 ± 0.70 |
| Change at Month 54 | -0.74 ± 0.67 |
| Change at Month 57 | -0.78 ± 0.76 |
| Change at Month 60 | -0.79 ± 0.74 |
| Change at Month 63 | -0.77 ± 0.74 |
| Change at Month 66 | -0.79 ± 0.73 |
| Change at Month 69 | -0.82 ± 0.76 |
| Change at Month 72 | -0.81 ± 0.74 |
| Change at Month 75 | -0.80 ± 0.79 |
| Change at Month 78 | -0.89 ± 0.80 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.38 ± 0.45 |
| Change at Month 3 | -0.31 ± 0.43 |
| Change at Month 6 | -0.34 ± 0.42 |
| Change at Month 9 | -0.40 ± 0.40 |
| Change at Month 12 | -0.39 ± 0.41 |
| Change at Month 15 | -0.38 ± 0.42 |
| Change at Month 18 | -0.41 ± 0.35 |
| Change at Month 21 | -0.48 ± 0.35 |
| Change at Month 24 | -0.41 ± 0.35 |
| Change at Month 27 | -0.40 ± 0.47 |
| Change at Month 30 | -0.36 ± 0.45 |
| Change at Month 33 | -0.34 ± 0.52 |
| Change at Month 36 | -0.36 ± 0.56 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -0.48 ± 0.49 |
| Change at Month 3 | -0.44 ± 0.49 |
| Change at Month 6 | -0.44 ± 0.48 |
| Change at Month 9 | -0.37 ± 0.54 |
| Change at Month 12 | -0.41 ± 0.44 |
| Change at Month 15 | -0.37 ± 0.52 |
| Change at Month 18 | -0.34 ± 0.65 |
| Change at Month 21 | -0.46 ± 0.63 |
| Change at Month 24 | -0.42 ± 0.74 |
| Change at Month 27 | -0.44 ± 0.65 |
| Change at Month 30 | -0.41 ± 0.60 |
| Change at Month 33 | -0.49 ± 0.60 |
| Change at Month 36 | -0.67 ± 0.55 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.54 ± 3.19 |
| Change at Month 3 | -4.94 ± 2.92 |
| Change at Month 6 | -5.16 ± 2.85 |
| Change at Month 9 | -5.23 ± 2.69 |
| Change at Month 12 | -4.93 ± 2.81 |
| Change at Month 15 | -4.59 ± 2.91 |
| Change at Month 18 | -4.47 ± 3.18 |
| Change at Month 21 | -4.97 ± 2.92 |
| Change at Month 24 | -4.76 ± 3.01 |
| Change at Month 27 | -5.06 ± 3.12 |
| Change at Month 30 | -5.59 ± 3.33 |
| Change at Month 33 | -4.63 ± 3.23 |
| Change at Month 36 | -4.50 ± 3.72 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.70 ± 3.14 |
| Change at Month 3 | -5.19 ± 2.79 |
| Change at Month 6 | -5.26 ± 2.79 |
| Change at Month 9 | -5.33 ± 2.55 |
| Change at Month 12 | -5.06 ± 2.65 |
| Change at Month 15 | -4.89 ± 2.60 |
| Change at Month 18 | -4.78 ± 3.05 |
| Change at Month 21 | -5.35 ± 2.73 |
| Change at Month 24 | -5.12 ± 2.92 |
| Change at Month 27 | -5.26 ± 2.97 |
| Change at Month 30 | -6.00 ± 3.03 |
| Change at Month 33 | -4.75 ± 3.06 |
| Change at Month 36 | -4.90 ± 3.65 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -3.16 ± 2.75 |
| Change at Month 3 | -3.28 ± 2.72 |
| Change at Month 6 | -3.60 ± 2.66 |
| Change at Month 9 | -3.66 ± 2.68 |
| Change at Month 12 | -3.74 ± 2.73 |
| Change at Month 15 | -3.76 ± 2.62 |
| Change at Month 18 | -3.89 ± 2.65 |
| Change at Month 21 | -3.77 ± 2.65 |
| Change at Month 24 | -3.75 ± 2.82 |
| Change at Month 27 | -3.99 ± 2.63 |
| Change at Month 30 | -3.83 ± 2.74 |
| Change at Month 33 | -3.81 ± 2.78 |
| Change at Month 36 | -3.86 ± 2.82 |
| Change at Month 39 | -3.71 ± 2.93 |
| Change at Month 42 | -3.74 ± 2.76 |
| Change at Month 45 | -3.88 ± 2.66 |
| Change at Month 48 | -4.08 ± 2.63 |
| Change at Month 51 | -4.15 ± 2.58 |
| Change at Month 54 | -4.16 ± 2.52 |
| Change at Month 57 | -4.04 ± 2.75 |
| Change at Month 60 | -3.94 ± 3.03 |
| Change at Month 63 | -4.37 ± 2.82 |
| Change at Month 66 | -4.24 ± 2.87 |
| Change at Month 69 | -4.34 ± 2.85 |
| Change at Month 72 | -4.21 ± 2.95 |
| Change at Month 75 | -4.28 ± 2.96 |
| Change at Month 78 | -4.21 ± 3.09 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -3.32 ± 2.61 |
| Change at Month 3 | -2.50 ± 3.03 |
| Change at Month 6 | -3.25 ± 1.99 |
| Change at Month 9 | -3.00 ± 3.13 |
| Change at Month 12 | -3.77 ± 1.86 |
| Change at Month 15 | -2.50 ± 3.07 |
| Change at Month 18 | -3.71 ± 1.83 |
| Change at Month 21 | -3.75 ± 1.76 |
| Change at Month 24 | -3.63 ± 1.86 |
| Change at Month 27 | -3.36 ± 2.23 |
| Change at Month 30 | -3.45 ± 2.35 |
| Change at Month 33 | -3.91 ± 1.92 |
| Change at Month 36 | -3.63 ± 2.01 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.07 ± 2.67 |
| Change at Month 3 | -4.34 ± 2.48 |
| Change at Month 6 | -4.77 ± 2.69 |
| Change at Month 9 | -3.60 ± 2.69 |
| Change at Month 12 | -4.70 ± 2.84 |
| Change at Month 15 | -3.90 ± 2.63 |
| Change at Month 18 | -3.73 ± 3.49 |
| Change at Month 21 | -3.92 ± 3.02 |
| Change at Month 24 | -4.42 ± 2.58 |
| Change at Month 27 | -3.79 ± 4.06 |
| Change at Month 30 | -4.25 ± 2.73 |
| Change at Month 33 | -3.91 ± 3.27 |
| Change at Month 36 | -4.67 ± 3.08 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.53 ± 3.08 |
| Change at Month 3 | -5.04 ± 2.66 |
| Change at Month 6 | -5.11 ± 2.98 |
| Change at Month 9 | -5.38 ± 2.62 |
| Change at Month 12 | -4.85 ± 2.91 |
| Change at Month 15 | -4.44 ± 3.01 |
| Change at Month 18 | -4.40 ± 3.36 |
| Change at Month 21 | -4.86 ± 3.03 |
| Change at Month 24 | -4.57 ± 3.23 |
| Change at Month 27 | -4.96 ± 3.28 |
| Change at Month 30 | -5.56 ± 3.45 |
| Change at Month 33 | -4.42 ± 3.45 |
| Change at Month 36 | -4.11 ± 3.74 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -4.71 ± 3.06 |
| Change at Month 3 | -5.32 ± 2.51 |
| Change at Month 6 | -5.25 ± 2.95 |
| Change at Month 9 | -5.51 ± 2.53 |
| Change at Month 12 | -5.12 ± 2.71 |
| Change at Month 15 | -4.83 ± 2.85 |
| Change at Month 18 | -4.94 ± 3.09 |
| Change at Month 21 | -5.48 ± 2.64 |
| Change at Month 24 | -5.24 ± 2.89 |
| Change at Month 27 | -5.58 ± 2.93 |
| Change at Month 30 | -6.38 ± 2.72 |
| Change at Month 33 | -5.25 ± 2.90 |
| Change at Month 36 | -5.50 ± 3.41 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -2.83 ± 2.51 |
| Change at Month 3 | -3.01 ± 2.62 |
| Change at Month 6 | -3.34 ± 2.51 |
| Change at Month 9 | -3.36 ± 2.59 |
| Change at Month 12 | -3.38 ± 2.77 |
| Change at Month 15 | -3.47 ± 2.43 |
| Change at Month 18 | -3.54 ± 2.74 |
| Change at Month 21 | -3.46 ± 2.75 |
| Change at Month 24 | -3.51 ± 2.84 |
| Change at Month 27 | -3.73 ± 2.65 |
| Change at Month 30 | -3.56 ± 2.86 |
| Change at Month 33 | -3.52 ± 2.58 |
| Change at Month 36 | -3.62 ± 2.81 |
| Change at Month 39 | -3.43 ± 2.83 |
| Change at Month 42 | -3.57 ± 2.72 |
| Change at Month 45 | -3.57 ± 2.77 |
| Change at Month 48 | -3.84 ± 2.63 |
| Change at Month 51 | -3.78 ± 2.69 |
| Change at Month 54 | -4.02 ± 2.73 |
| Change at Month 57 | -3.92 ± 2.91 |
| Change at Month 60 | -3.82 ± 3.11 |
| Change at Month 63 | -4.22 ± 3.02 |
| Change at Month 66 | -3.88 ± 2.83 |
| Change at Month 69 | -3.98 ± 2.89 |
| Change at Month 72 | -3.80 ± 3.08 |
| Change at Month 75 | -3.87 ± 3.02 |
| Change at Month 78 | -3.88 ± 3.11 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -1.32 ± 2.59 |
| Change at Month 3 | -1.69 ± 2.04 |
| Change at Month 6 | -2.03 ± 1.88 |
| Change at Month 9 | -2.93 ± 1.80 |
| Change at Month 12 | -2.27 ± 1.93 |
| Change at Month 15 | -2.62 ± 1.56 |
| Change at Month 18 | -2.75 ± 1.47 |
| Change at Month 21 | -2.83 ± 1.57 |
| Change at Month 24 | -2.71 ± 2.10 |
| Change at Month 27 | -2.68 ± 1.72 |
| Change at Month 30 | -2.20 ± 2.29 |
| Change at Month 33 | -2.50 ± 1.43 |
| Change at Month 36 | -2.79 ± 1.62 |
CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -2.96 ± 3.01 |
| Change at Month 3 | -3.03 ± 3.01 |
| Change at Month 6 | -3.43 ± 2.85 |
| Change at Month 9 | -2.60 ± 2.68 |
| Change at Month 12 | -3.17 ± 3.54 |
| Change at Month 15 | -2.53 ± 3.32 |
| Change at Month 18 | -3.00 ± 3.43 |
| Change at Month 21 | -2.75 ± 3.31 |
| Change at Month 24 | -3.42 ± 3.21 |
| Change at Month 27 | -3.54 ± 3.58 |
| Change at Month 30 | -3.75 ± 3.33 |
| Change at Month 33 | -3.41 ± 3.53 |
| Change at Month 36 | -3.89 ± 3.37 |
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 30 at Month 1 | 84.71 |
| JIA ACR 30 at Month 3 | 86.59 |
| JIA ACR 30 at Month 6 | 92.31 |
| JIA ACR 30 at Month 9 | 94.74 |
| JIA ACR 30 at Month 12 | 94.92 |
| JIA ACR 30 at Month 15 | 85.42 |
| JIA ACR 30 at Month 18 | 84.62 |
| JIA ACR 30 at Month 21 | 93.10 |
| JIA ACR 30 at Month 24 | 88.89 |
| JIA ACR 30 at Month 27 | 91.67 |
| JIA ACR 30 at Month 30 | 94.12 |
| JIA ACR 30 at Month 33 | 91.67 |
| JIA ACR 30 at Month 36 | 100.00 |
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 30 at Month 1 | 84.42 |
| JIA ACR 30 at Month 3 | 87.84 |
| JIA ACR 30 at Month 6 | 91.67 |
| JIA ACR 30 at Month 9 | 94.20 |
| JIA ACR 30 at Month 12 | 96.15 |
| JIA ACR 30 at Month 15 | 85.00 |
| JIA ACR 30 at Month 18 | 87.50 |
| JIA ACR 30 at Month 21 | 95.65 |
| JIA ACR 30 at Month 24 | 95.24 |
| JIA ACR 30 at Month 27 | 94.74 |
| JIA ACR 30 at Month 30 | 100.00 |
| JIA ACR 30 at Month 33 | 87.50 |
| JIA ACR 30 at Month 36 | 100.00 |
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 30 at Month 1 | 89.84 |
| JIA ACR 30 at Month 3 | 89.05 |
| JIA ACR 30 at Month 6 | 92.91 |
| JIA ACR 30 at Month 9 | 92.25 |
| JIA ACR 30 at Month 12 | 92.86 |
| JIA ACR 30 at Month 15 | 95.59 |
| JIA ACR 30 at Month 18 | 89.60 |
| JIA ACR 30 at Month 21 | 93.44 |
| JIA ACR 30 at Month 24 | 92.79 |
| JIA ACR 30 at Month 27 | 97.27 |
| JIA ACR 30 at Month 30 | 92.59 |
| JIA ACR 30 at Month 33 | 96.40 |
| JIA ACR 30 at Month 36 | 96.33 |
| JIA ACR 30 at Month 39 | 94.29 |
| JIA ACR 30 at Month 42 | 95.05 |
| JIA ACR 30 at Month 45 | 94.51 |
| JIA ACR 30 at Month 48 | 97.50 |
| JIA ACR 30 at Month 51 | 94.03 |
| JIA ACR 30 at Month 54 | 98.18 |
| JIA ACR 30 at Month 57 | 94.34 |
| JIA ACR 30 at Month 60 | 93.48 |
| JIA ACR 30 at Month 63 | 90.24 |
| JIA ACR 30 at Month 66 | 87.18 |
| JIA ACR 30 at Month 69 | 92.50 |
| JIA ACR 30 at Month 72 | 89.74 |
| JIA ACR 30 at Month 75 | 94.29 |
| JIA ACR 30 at Month 78 | 89.29 |
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 30 at Month 1 | 90.91 |
| JIA ACR 30 at Month 3 | 85.71 |
| JIA ACR 30 at Month 6 | 87.50 |
| JIA ACR 30 at Month 9 | 92.31 |
| JIA ACR 30 at Month 12 | 86.67 |
| JIA ACR 30 at Month 15 | 92.31 |
| JIA ACR 30 at Month 18 | 100.00 |
| JIA ACR 30 at Month 21 | 100.00 |
| JIA ACR 30 at Month 24 | 90.91 |
| JIA ACR 30 at Month 27 | 100.00 |
| JIA ACR 30 at Month 30 | 90.91 |
| JIA ACR 30 at Month 33 | 100.00 |
| JIA ACR 30 at Month 36 | 83.33 |
JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 30 at Month 1 | 86.67 |
| JIA ACR 30 at Month 3 | 93.33 |
| JIA ACR 30 at Month 6 | 100.00 |
| JIA ACR 30 at Month 9 | 93.33 |
| JIA ACR 30 at Month 12 | 93.33 |
| JIA ACR 30 at Month 15 | 80.00 |
| JIA ACR 30 at Month 18 | 76.92 |
| JIA ACR 30 at Month 21 | 91.67 |
| JIA ACR 30 at Month 24 | 90.91 |
| JIA ACR 30 at Month 27 | 75.00 |
| JIA ACR 30 at Month 30 | 83.33 |
| JIA ACR 30 at Month 33 | 72.73 |
| JIA ACR 30 at Month 36 | 100.00 |
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 50 at Month 1 | 75.58 |
| JIA ACR 50 at Month 3 | 82.93 |
| JIA ACR 50 at Month 6 | 91.03 |
| JIA ACR 50 at Month 9 | 86.84 |
| JIA ACR 50 at Month 12 | 89.83 |
| JIA ACR 50 at Month 15 | 83.33 |
| JIA ACR 50 at Month 18 | 76.92 |
| JIA ACR 50 at Month 21 | 89.66 |
| JIA ACR 50 at Month 24 | 88.89 |
| JIA ACR 50 at Month 27 | 87.50 |
| JIA ACR 50 at Month 30 | 94.12 |
| JIA ACR 50 at Month 33 | 83.33 |
| JIA ACR 50 at Month 36 | 100.00 |
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 50 at Month 1 | 77.92 |
| JIA ACR 50 at Month 3 | 85.14 |
| JIA ACR 50 at Month 6 | 90.28 |
| JIA ACR 50 at Month 9 | 88.41 |
| JIA ACR 50 at Month 12 | 92.31 |
| JIA ACR 50 at Month 15 | 85.00 |
| JIA ACR 50 at Month 18 | 84.38 |
| JIA ACR 50 at Month 21 | 95.65 |
| JIA ACR 50 at Month 24 | 95.24 |
| JIA ACR 50 at Month 27 | 89.47 |
| JIA ACR 50 at Month 30 | 100.00 |
| JIA ACR 50 at Month 33 | 87.50 |
| JIA ACR 50 at Month 36 | 100.00 |
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 50 at Month 1 | 79.84 |
| JIA ACR 50 at Month 3 | 83.94 |
| JIA ACR 50 at Month 6 | 87.23 |
| JIA ACR 50 at Month 9 | 87.32 |
| JIA ACR 50 at Month 12 | 87.86 |
| JIA ACR 50 at Month 15 | 90.44 |
| JIA ACR 50 at Month 18 | 86.40 |
| JIA ACR 50 at Month 21 | 87.70 |
| JIA ACR 50 at Month 24 | 90.99 |
| JIA ACR 50 at Month 27 | 92.73 |
| JIA ACR 50 at Month 30 | 92.59 |
| JIA ACR 50 at Month 33 | 92.79 |
| JIA ACR 50 at Month 36 | 93.58 |
| JIA ACR 50 at Month 39 | 90.48 |
| JIA ACR 50 at Month 42 | 92.08 |
| JIA ACR 50 at Month 45 | 93.41 |
| JIA ACR 50 at Month 48 | 93.75 |
| JIA ACR 50 at Month 51 | 92.54 |
| JIA ACR 50 at Month 54 | 96.36 |
| JIA ACR 50 at Month 57 | 94.34 |
| JIA ACR 50 at Month 60 | 91.30 |
| JIA ACR 50 at Month 63 | 90.24 |
| JIA ACR 50 at Month 66 | 87.18 |
| JIA ACR 50 at Month 69 | 92.50 |
| JIA ACR 50 at Month 72 | 89.74 |
| JIA ACR 50 at Month 75 | 91.43 |
| JIA ACR 50 at Month 78 | 89.29 |
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 50 at Month 1 | 72.73 |
| JIA ACR 50 at Month 3 | 85.71 |
| JIA ACR 50 at Month 6 | 87.50 |
| JIA ACR 50 at Month 9 | 92.31 |
| JIA ACR 50 at Month 12 | 80.00 |
| JIA ACR 50 at Month 15 | 84.62 |
| JIA ACR 50 at Month 18 | 100.00 |
| JIA ACR 50 at Month 21 | 100.00 |
| JIA ACR 50 at Month 24 | 90.91 |
| JIA ACR 50 at Month 27 | 100.00 |
| JIA ACR 50 at Month 30 | 90.91 |
| JIA ACR 50 at Month 33 | 100.00 |
| JIA ACR 50 at Month 36 | 83.33 |
JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 50 at Month 1 | 80.00 |
| JIA ACR 50 at Month 3 | 86.67 |
| JIA ACR 50 at Month 6 | 100.00 |
| JIA ACR 50 at Month 9 | 93.33 |
| JIA ACR 50 at Month 12 | 86.67 |
| JIA ACR 50 at Month 15 | 80.00 |
| JIA ACR 50 at Month 18 | 76.92 |
| JIA ACR 50 at Month 21 | 83.33 |
| JIA ACR 50 at Month 24 | 90.91 |
| JIA ACR 50 at Month 27 | 75.00 |
| JIA ACR 50 at Month 30 | 66.67 |
| JIA ACR 50 at Month 33 | 63.64 |
| JIA ACR 50 at Month 36 | 87.50 |
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 70 at Month 1 | 63.95 |
| JIA ACR 70 at Month 3 | 71.95 |
| JIA ACR 70 at Month 6 | 78.21 |
| JIA ACR 70 at Month 9 | 76.32 |
| JIA ACR 70 at Month 12 | 76.27 |
| JIA ACR 70 at Month 15 | 68.75 |
| JIA ACR 70 at Month 18 | 69.23 |
| JIA ACR 70 at Month 21 | 72.41 |
| JIA ACR 70 at Month 24 | 77.78 |
| JIA ACR 70 at Month 27 | 75.00 |
| JIA ACR 70 at Month 30 | 76.47 |
| JIA ACR 70 at Month 33 | 83.33 |
| JIA ACR 70 at Month 36 | 88.89 |
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 70 at Month 1 | 66.23 |
| JIA ACR 70 at Month 3 | 74.32 |
| JIA ACR 70 at Month 6 | 79.17 |
| JIA ACR 70 at Month 9 | 76.81 |
| JIA ACR 70 at Month 12 | 76.92 |
| JIA ACR 70 at Month 15 | 72.50 |
| JIA ACR 70 at Month 18 | 75.00 |
| JIA ACR 70 at Month 21 | 78.26 |
| JIA ACR 70 at Month 24 | 80.95 |
| JIA ACR 70 at Month 27 | 78.95 |
| JIA ACR 70 at Month 30 | 84.62 |
| JIA ACR 70 at Month 33 | 87.50 |
| JIA ACR 70 at Month 36 | 80.00 |
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 70 at Month 1 | 60.00 |
| JIA ACR 70 at Month 3 | 67.63 |
| JIA ACR 70 at Month 6 | 73.05 |
| JIA ACR 70 at Month 9 | 71.83 |
| JIA ACR 70 at Month 12 | 73.05 |
| JIA ACR 70 at Month 15 | 78.36 |
| JIA ACR 70 at Month 18 | 75.20 |
| JIA ACR 70 at Month 21 | 77.05 |
| JIA ACR 70 at Month 24 | 82.88 |
| JIA ACR 70 at Month 27 | 80.00 |
| JIA ACR 70 at Month 30 | 78.70 |
| JIA ACR 70 at Month 33 | 82.88 |
| JIA ACR 70 at Month 36 | 86.24 |
| JIA ACR 70 at Month 39 | 80.19 |
| JIA ACR 70 at Month 42 | 82.00 |
| JIA ACR 70 at Month 45 | 86.81 |
| JIA ACR 70 at Month 48 | 87.50 |
| JIA ACR 70 at Month 51 | 88.06 |
| JIA ACR 70 at Month 54 | 92.73 |
| JIA ACR 70 at Month 57 | 88.68 |
| JIA ACR 70 at Month 60 | 82.61 |
| JIA ACR 70 at Month 63 | 90.24 |
| JIA ACR 70 at Month 66 | 84.62 |
| JIA ACR 70 at Month 69 | 92.50 |
| JIA ACR 70 at Month 72 | 89.74 |
| JIA ACR 70 at Month 75 | 85.29 |
| JIA ACR 70 at Month 78 | 85.71 |
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 70 at Month 1 | 58.33 |
| JIA ACR 70 at Month 3 | 46.67 |
| JIA ACR 70 at Month 6 | 76.47 |
| JIA ACR 70 at Month 9 | 76.92 |
| JIA ACR 70 at Month 12 | 60.00 |
| JIA ACR 70 at Month 15 | 61.54 |
| JIA ACR 70 at Month 18 | 75.00 |
| JIA ACR 70 at Month 21 | 91.67 |
| JIA ACR 70 at Month 24 | 63.64 |
| JIA ACR 70 at Month 27 | 75.00 |
| JIA ACR 70 at Month 30 | 81.82 |
| JIA ACR 70 at Month 33 | 90.91 |
| JIA ACR 70 at Month 36 | 66.67 |
JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 70 at Month 1 | 52.94 |
| JIA ACR 70 at Month 3 | 86.67 |
| JIA ACR 70 at Month 6 | 73.33 |
| JIA ACR 70 at Month 9 | 80.00 |
| JIA ACR 70 at Month 12 | 86.67 |
| JIA ACR 70 at Month 15 | 66.67 |
| JIA ACR 70 at Month 18 | 76.92 |
| JIA ACR 70 at Month 21 | 72.73 |
| JIA ACR 70 at Month 24 | 90.91 |
| JIA ACR 70 at Month 27 | 66.67 |
| JIA ACR 70 at Month 30 | 66.67 |
| JIA ACR 70 at Month 33 | 63.64 |
| JIA ACR 70 at Month 36 | 75.00 |
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 90 at Month 1 | 40.23 |
| JIA ACR 90 at Month 3 | 51.19 |
| JIA ACR 90 at Month 6 | 48.10 |
| JIA ACR 90 at Month 9 | 49.35 |
| JIA ACR 90 at Month 12 | 48.33 |
| JIA ACR 90 at Month 15 | 43.75 |
| JIA ACR 90 at Month 18 | 51.28 |
| JIA ACR 90 at Month 21 | 44.83 |
| JIA ACR 90 at Month 24 | 51.85 |
| JIA ACR 90 at Month 27 | 66.67 |
| JIA ACR 90 at Month 30 | 58.82 |
| JIA ACR 90 at Month 33 | 58.33 |
| JIA ACR 90 at Month 36 | 44.44 |
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 90 at Month 1 | 42.86 |
| JIA ACR 90 at Month 3 | 55.41 |
| JIA ACR 90 at Month 6 | 50.00 |
| JIA ACR 90 at Month 9 | 49.28 |
| JIA ACR 90 at Month 12 | 49.06 |
| JIA ACR 90 at Month 15 | 47.50 |
| JIA ACR 90 at Month 18 | 53.13 |
| JIA ACR 90 at Month 21 | 47.83 |
| JIA ACR 90 at Month 24 | 52.38 |
| JIA ACR 90 at Month 27 | 73.68 |
| JIA ACR 90 at Month 30 | 69.23 |
| JIA ACR 90 at Month 33 | 62.50 |
| JIA ACR 90 at Month 36 | 60.00 |
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 90 at Month 1 | 33.57 |
| JIA ACR 90 at Month 3 | 36.99 |
| JIA ACR 90 at Month 6 | 43.45 |
| JIA ACR 90 at Month 9 | 48.25 |
| JIA ACR 90 at Month 12 | 45.00 |
| JIA ACR 90 at Month 15 | 54.48 |
| JIA ACR 90 at Month 18 | 49.60 |
| JIA ACR 90 at Month 21 | 48.33 |
| JIA ACR 90 at Month 24 | 54.05 |
| JIA ACR 90 at Month 27 | 55.86 |
| JIA ACR 90 at Month 30 | 56.48 |
| JIA ACR 90 at Month 33 | 63.06 |
| JIA ACR 90 at Month 36 | 65.45 |
| JIA ACR 90 at Month 39 | 62.96 |
| JIA ACR 90 at Month 42 | 61.39 |
| JIA ACR 90 at Month 45 | 65.93 |
| JIA ACR 90 at Month 48 | 64.20 |
| JIA ACR 90 at Month 51 | 66.67 |
| JIA ACR 90 at Month 54 | 64.29 |
| JIA ACR 90 at Month 57 | 59.26 |
| JIA ACR 90 at Month 60 | 58.70 |
| JIA ACR 90 at Month 63 | 63.41 |
| JIA ACR 90 at Month 66 | 61.54 |
| JIA ACR 90 at Month 69 | 65.00 |
| JIA ACR 90 at Month 72 | 64.10 |
| JIA ACR 90 at Month 75 | 65.71 |
| JIA ACR 90 at Month 78 | 60.71 |
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 90 at Month 1 | 30.77 |
| JIA ACR 90 at Month 3 | 18.75 |
| JIA ACR 90 at Month 6 | 33.33 |
| JIA ACR 90 at Month 9 | 40.00 |
| JIA ACR 90 at Month 12 | 33.33 |
| JIA ACR 90 at Month 15 | 46.15 |
| JIA ACR 90 at Month 18 | 50.00 |
| JIA ACR 90 at Month 21 | 50.00 |
| JIA ACR 90 at Month 24 | 36.36 |
| JIA ACR 90 at Month 27 | 41.67 |
| JIA ACR 90 at Month 30 | 27.27 |
| JIA ACR 90 at Month 33 | 36.36 |
| JIA ACR 90 at Month 36 | 16.67 |
JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 90 at Month 1 | 44.44 |
| JIA ACR 90 at Month 3 | 58.82 |
| JIA ACR 90 at Month 6 | 53.33 |
| JIA ACR 90 at Month 9 | 53.33 |
| JIA ACR 90 at Month 12 | 60.00 |
| JIA ACR 90 at Month 15 | 60.00 |
| JIA ACR 90 at Month 18 | 61.54 |
| JIA ACR 90 at Month 21 | 58.33 |
| JIA ACR 90 at Month 24 | 81.82 |
| JIA ACR 90 at Month 27 | 66.67 |
| JIA ACR 90 at Month 30 | 58.33 |
| JIA ACR 90 at Month 33 | 54.55 |
| JIA ACR 90 at Month 36 | 62.50 |
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 100 at Month 1 | 26.44 |
| JIA ACR 100 at Month 3 | 36.90 |
| JIA ACR 100 at Month 6 | 37.97 |
| JIA ACR 100 at Month 9 | 32.47 |
| JIA ACR 100 at Month 12 | 31.67 |
| JIA ACR 100 at Month 15 | 35.42 |
| JIA ACR 100 at Month 18 | 46.15 |
| JIA ACR 100 at Month 21 | 41.38 |
| JIA ACR 100 at Month 24 | 44.44 |
| JIA ACR 100 at Month 27 | 45.83 |
| JIA ACR 100 at Month 30 | 52.94 |
| JIA ACR 100 at Month 33 | 25.00 |
| JIA ACR 100 at Month 36 | 44.44 |
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 100 at Month 1 | 27.27 |
| JIA ACR 100 at Month 3 | 39.19 |
| JIA ACR 100 at Month 6 | 38.89 |
| JIA ACR 100 at Month 9 | 33.33 |
| JIA ACR 100 at Month 12 | 32.08 |
| JIA ACR 100 at Month 15 | 37.50 |
| JIA ACR 100 at Month 18 | 50.00 |
| JIA ACR 100 at Month 21 | 43.48 |
| JIA ACR 100 at Month 24 | 47.62 |
| JIA ACR 100 at Month 27 | 47.37 |
| JIA ACR 100 at Month 30 | 61.54 |
| JIA ACR 100 at Month 33 | 37.50 |
| JIA ACR 100 at Month 36 | 60.00 |
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 100 at Month 1 | 26.57 |
| JIA ACR 100 at Month 3 | 29.93 |
| JIA ACR 100 at Month 6 | 38.10 |
| JIA ACR 100 at Month 9 | 39.86 |
| JIA ACR 100 at Month 12 | 40.29 |
| JIA ACR 100 at Month 15 | 46.67 |
| JIA ACR 100 at Month 18 | 41.94 |
| JIA ACR 100 at Month 21 | 39.67 |
| JIA ACR 100 at Month 24 | 45.95 |
| JIA ACR 100 at Month 27 | 47.27 |
| JIA ACR 100 at Month 30 | 47.71 |
| JIA ACR 100 at Month 33 | 48.65 |
| JIA ACR 100 at Month 36 | 57.27 |
| JIA ACR 100 at Month 39 | 50.00 |
| JIA ACR 100 at Month 42 | 48.51 |
| JIA ACR 100 at Month 45 | 51.09 |
| JIA ACR 100 at Month 48 | 52.50 |
| JIA ACR 100 at Month 51 | 57.97 |
| JIA ACR 100 at Month 54 | 55.36 |
| JIA ACR 100 at Month 57 | 55.56 |
| JIA ACR 100 at Month 60 | 56.52 |
| JIA ACR 100 at Month 63 | 57.50 |
| JIA ACR 100 at Month 66 | 56.41 |
| JIA ACR 100 at Month 69 | 58.97 |
| JIA ACR 100 at Month 72 | 61.54 |
| JIA ACR 100 at Month 75 | 54.29 |
| JIA ACR 100 at Month 78 | 57.14 |
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 100 at Month 1 | 28.57 |
| JIA ACR 100 at Month 3 | 17.65 |
| JIA ACR 100 at Month 6 | 33.33 |
| JIA ACR 100 at Month 9 | 33.33 |
| JIA ACR 100 at Month 12 | 26.67 |
| JIA ACR 100 at Month 15 | 46.15 |
| JIA ACR 100 at Month 18 | 33.33 |
| JIA ACR 100 at Month 21 | 41.67 |
| JIA ACR 100 at Month 24 | 27.27 |
| JIA ACR 100 at Month 27 | 41.67 |
| JIA ACR 100 at Month 30 | 27.27 |
| JIA ACR 100 at Month 33 | 36.36 |
| JIA ACR 100 at Month 36 | 16.67 |
JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR 100 at Month 1 | 38.89 |
| JIA ACR 100 at Month 3 | 41.18 |
| JIA ACR 100 at Month 6 | 53.33 |
| JIA ACR 100 at Month 9 | 40.00 |
| JIA ACR 100 at Month 12 | 33.33 |
| JIA ACR 100 at Month 15 | 53.33 |
| JIA ACR 100 at Month 18 | 46.15 |
| JIA ACR 100 at Month 21 | 58.33 |
| JIA ACR 100 at Month 24 | 81.82 |
| JIA ACR 100 at Month 27 | 66.67 |
| JIA ACR 100 at Month 30 | 58.33 |
| JIA ACR 100 at Month 33 | 54.55 |
| JIA ACR 100 at Month 36 | 62.50 |
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree Celsius(C) oral or \>38.6 degree C rectal on \>=2 consecutive days.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Disease flare at Month 6 | 5.0 |
| Disease flare at Month 9 | 9.3 |
| Disease flare at Month 12 | 1.7 |
| Disease flare at Month 15 | 8.2 |
| Disease flare at Month 18 | 7.9 |
| Disease flare at Month 21 | 0 |
| Disease flare at Month 24 | 11.5 |
| Disease flare at Month 27 | 4.3 |
| Disease flare at Month 30 | 0 |
| Disease flare at Month 33 | 0 |
| Disease flare at Month 36 | 0 |
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree C oral or \>38.6 degree C rectal on \>=2 consecutive days.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Disease flare at Month 6 | 5.6 |
| Disease flare at Month 9 | 10.1 |
| Disease flare at Month 12 | 1.9 |
| Disease flare at Month 15 | 9.8 |
| Disease flare at Month 18 | 6.3 |
| Disease flare at Month 21 | 0 |
| Disease flare at Month 24 | 14.3 |
| Disease flare at Month 27 | 5.3 |
| Disease flare at Month 30 | 0 |
| Disease flare at Month 33 | 0 |
| Disease flare at Month 36 | 0 |
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Disease flare at Month 6 | 3.9 |
| Disease flare at Month 9 | 4.8 |
| Disease flare at Month 12 | 5.6 |
| Disease flare at Month 15 | 3.6 |
| Disease flare at Month 18 | 2.3 |
| Disease flare at Month 21 | 3.9 |
| Disease flare at Month 24 | 1.8 |
| Disease flare at Month 27 | 4.3 |
| Disease flare at Month 30 | 2.7 |
| Disease flare at Month 33 | 2.7 |
| Disease flare at Month 36 | 0.9 |
| Disease flare at Month 39 | 4.8 |
| Disease flare at Month 42 | 1.9 |
| Disease flare at Month 45 | 1.1 |
| Disease flare at Month 48 | 1.3 |
| Disease flare at Month 51 | 2.9 |
| Disease flare at Month 54 | 1.8 |
| Disease flare at Month 57 | 1.9 |
| Disease flare at Month 60 | 4.5 |
| Disease flare at Month 63 | 2.5 |
| Disease flare at Month 66 | 5.7 |
| Disease flare at Month 69 | 0 |
| Disease flare at Month 72 | 5.4 |
| Disease flare at Month 75 | 3.1 |
| Disease flare at Month 78 | 0 |
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Disease flare at Month 6 | 5.9 |
| Disease flare at Month 9 | 0 |
| Disease flare at Month 12 | 0 |
| Disease flare at Month 15 | 0 |
| Disease flare at Month 18 | 0 |
| Disease flare at Month 21 | 0 |
| Disease flare at Month 24 | 8.3 |
| Disease flare at Month 27 | 9.1 |
| Disease flare at Month 30 | 0 |
| Disease flare at Month 33 | 0 |
| Disease flare at Month 36 | 9.1 |
Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Disease flare at Month 6 | 0 |
| Disease flare at Month 9 | 7.1 |
| Disease flare at Month 12 | 6.7 |
| Disease flare at Month 15 | 0 |
| Disease flare at Month 18 | 0 |
| Disease flare at Month 21 | 8.3 |
| Disease flare at Month 24 | 9.1 |
| Disease flare at Month 27 | 8.3 |
| Disease flare at Month 30 | 7.7 |
| Disease flare at Month 33 | 0 |
| Disease flare at Month 36 | 10.0 |
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Inactive Disease Based on CRP: Month 1 | 13.79 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 3 | 16.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 6 | 17.72 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 9 | 19.74 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 12 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 15 | 25.53 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 18 | 35.90 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 21 | 32.14 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 24 | 29.63 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 27 | 34.78 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 30 | 41.18 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 33 | 16.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 36 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 1 | 17.05 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 3 | 19.05 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 6 | 20.25 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 9 | 19.74 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 12 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 15 | 27.08 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 18 | 35.90 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 21 | 37.93 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 24 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 27 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 30 | 41.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 33 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 36 | 33.33 |
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Inactive Disease Based on CRP: Month 1 | 14.47 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 3 | 16.44 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 6 | 16.90 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 9 | 19.12 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 12 | 24.53 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 15 | 25.64 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 18 | 37.50 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 21 | 31.82 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 24 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 27 | 38.89 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 30 | 53.85 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 33 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 36 | 40.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 1 | 18.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 3 | 19.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 6 | 19.72 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 9 | 19.12 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 12 | 26.42 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 15 | 27.50 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 18 | 40.63 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 21 | 43.48 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 24 | 38.10 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 27 | 36.84 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 30 | 53.85 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 33 | 37.50 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 36 | 40.00 |
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Inactive Disease Based on CRP: Month 1 | 22.22 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 3 | 28.09 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 6 | 30.12 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 9 | 32.91 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 12 | 31.41 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 15 | 33.56 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 18 | 33.82 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 21 | 35.61 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 24 | 38.02 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 27 | 42.50 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 30 | 47.46 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 33 | 41.03 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 36 | 44.54 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 39 | 42.61 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 42 | 43.75 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 45 | 44.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 48 | 44.32 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 51 | 43.42 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 54 | 46.15 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 57 | 48.39 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 60 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 63 | 48.89 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 66 | 40.91 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 69 | 48.84 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 72 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 75 | 44.74 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 78 | 40.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 1 | 23.76 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 3 | 28.65 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 6 | 30.12 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 9 | 35.44 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 12 | 32.05 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 15 | 35.62 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 18 | 35.56 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 21 | 36.57 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 24 | 38.02 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 27 | 40.34 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 30 | 43.59 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 33 | 39.83 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 36 | 44.92 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 39 | 41.74 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 42 | 41.96 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 45 | 42.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 48 | 43.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 51 | 46.05 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 54 | 47.69 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 57 | 45.16 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 60 | 45.10 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 63 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 66 | 43.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 69 | 45.45 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 72 | 51.16 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 75 | 47.50 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 78 | 48.48 |
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Inactive Disease Based on CRP: Month 1 | 20.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 3 | 19.05 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 6 | 31.58 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 9 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 12 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 15 | 38.46 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 18 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 21 | 36.36 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 24 | 18.18 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 27 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 30 | 27.27 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 33 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 36 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 1 | 20.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 3 | 19.05 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 6 | 31.58 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 9 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 12 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 15 | 38.46 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 18 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 21 | 41.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 24 | 18.18 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 27 | 27.27 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 30 | 27.27 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 33 | 25.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 36 | 25.00 |
JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Inactive Disease Based on CRP: Month 1 | 22.22 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 3 | 11.11 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 6 | 33.33 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 9 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 12 | 18.75 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 15 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 18 | 38.46 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 21 | 38.46 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 24 | 45.45 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 27 | 18.18 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 30 | 53.85 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 33 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on CRP: Month 36 | 22.22 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 1 | 22.22 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 3 | 16.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 6 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 9 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 12 | 12.50 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 15 | 26.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 18 | 30.77 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 21 | 41.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 24 | 50.00 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 27 | 16.67 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 30 | 46.15 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 33 | 45.45 |
| JIA ACR Clinical Inactive Disease Based on ESR: Month 36 | 11.11 |
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the standardization of uveitis nomenclature \[SUN\] working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Remission Based on CRP: Month 9 | 7.89 |
| JIA ACR Clinical Remission Based on CRP: Month 12 | 5.00 |
| JIA ACR Clinical Remission Based on CRP: Month 15 | 4.26 |
| JIA ACR Clinical Remission Based on CRP: Month 18 | 10.26 |
| JIA ACR Clinical Remission Based on CRP: Month 21 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 24 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 27 | 8.70 |
| JIA ACR Clinical Remission Based on CRP: Month 30 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 33 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 36 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 9 | 9.21 |
| JIA ACR Clinical Remission Based on ESR: Month 12 | 3.33 |
| JIA ACR Clinical Remission Based on ESR: Month 15 | 4.17 |
| JIA ACR Clinical Remission Based on ESR: Month 18 | 10.26 |
| JIA ACR Clinical Remission Based on ESR: Month 21 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 24 | 11.11 |
| JIA ACR Clinical Remission Based on ESR: Month 27 | 4.17 |
| JIA ACR Clinical Remission Based on ESR: Month 30 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 33 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 36 | 0 |
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Remission Based on CRP: Month 9 | 8.82 |
| JIA ACR Clinical Remission Based on CRP: Month 12 | 3.77 |
| JIA ACR Clinical Remission Based on CRP: Month 15 | 5.13 |
| JIA ACR Clinical Remission Based on CRP: Month 18 | 9.38 |
| JIA ACR Clinical Remission Based on CRP: Month 21 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 24 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 27 | 11.11 |
| JIA ACR Clinical Remission Based on CRP: Month 30 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 33 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 36 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 9 | 10.29 |
| JIA ACR Clinical Remission Based on ESR: Month 12 | 1.89 |
| JIA ACR Clinical Remission Based on ESR: Month 15 | 5.00 |
| JIA ACR Clinical Remission Based on ESR: Month 18 | 9.38 |
| JIA ACR Clinical Remission Based on ESR: Month 21 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 24 | 14.29 |
| JIA ACR Clinical Remission Based on ESR: Month 27 | 5.26 |
| JIA ACR Clinical Remission Based on ESR: Month 30 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 33 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 36 | 0 |
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Remission Based on CRP: Month 9 | 18.35 |
| JIA ACR Clinical Remission Based on CRP: Month 12 | 4.49 |
| JIA ACR Clinical Remission Based on CRP: Month 15 | 3.42 |
| JIA ACR Clinical Remission Based on CRP: Month 18 | 5.15 |
| JIA ACR Clinical Remission Based on CRP: Month 21 | 2.27 |
| JIA ACR Clinical Remission Based on CRP: Month 24 | 3.31 |
| JIA ACR Clinical Remission Based on CRP: Month 27 | 4.17 |
| JIA ACR Clinical Remission Based on CRP: Month 30 | 1.69 |
| JIA ACR Clinical Remission Based on CRP: Month 33 | 1.71 |
| JIA ACR Clinical Remission Based on CRP: Month 36 | 0.84 |
| JIA ACR Clinical Remission Based on CRP: Month 39 | 0.87 |
| JIA ACR Clinical Remission Based on CRP: Month 42 | 1.79 |
| JIA ACR Clinical Remission Based on CRP: Month 45 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 48 | 3.41 |
| JIA ACR Clinical Remission Based on CRP: Month 51 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 54 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 57 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 60 | 5.77 |
| JIA ACR Clinical Remission Based on CRP: Month 63 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 66 | 2.27 |
| JIA ACR Clinical Remission Based on CRP: Month 69 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 72 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 75 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 78 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 9 | 19.62 |
| JIA ACR Clinical Remission Based on ESR: Month 12 | 5.13 |
| JIA ACR Clinical Remission Based on ESR: Month 15 | 5.48 |
| JIA ACR Clinical Remission Based on ESR: Month 18 | 5.19 |
| JIA ACR Clinical Remission Based on ESR: Month 21 | 1.49 |
| JIA ACR Clinical Remission Based on ESR: Month 24 | 3.31 |
| JIA ACR Clinical Remission Based on ESR: Month 27 | 1.68 |
| JIA ACR Clinical Remission Based on ESR: Month 30 | 0.85 |
| JIA ACR Clinical Remission Based on ESR: Month 33 | 0.85 |
| JIA ACR Clinical Remission Based on ESR: Month 36 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 39 | 1.74 |
| JIA ACR Clinical Remission Based on ESR: Month 42 | 1.79 |
| JIA ACR Clinical Remission Based on ESR: Month 45 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 48 | 2.27 |
| JIA ACR Clinical Remission Based on ESR: Month 51 | 1.32 |
| JIA ACR Clinical Remission Based on ESR: Month 54 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 57 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 60 | 5.88 |
| JIA ACR Clinical Remission Based on ESR: Month 63 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 66 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 69 | 2.27 |
| JIA ACR Clinical Remission Based on ESR: Month 72 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 75 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 78 | 0 |
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Remission Based on CRP: Month 9 | 13.33 |
| JIA ACR Clinical Remission Based on CRP: Month 12 | 6.67 |
| JIA ACR Clinical Remission Based on CRP: Month 15 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 18 | 8.33 |
| JIA ACR Clinical Remission Based on CRP: Month 21 | 18.18 |
| JIA ACR Clinical Remission Based on CRP: Month 24 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 27 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 30 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 33 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 36 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 9 | 13.33 |
| JIA ACR Clinical Remission Based on ESR: Month 12 | 6.67 |
| JIA ACR Clinical Remission Based on ESR: Month 15 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 18 | 16.67 |
| JIA ACR Clinical Remission Based on ESR: Month 21 | 8.33 |
| JIA ACR Clinical Remission Based on ESR: Month 24 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 27 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 30 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 33 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 36 | 0 |
JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JIA ACR Clinical Remission Based on CRP: Month 9 | 6.67 |
| JIA ACR Clinical Remission Based on CRP: Month 12 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 15 | 6.67 |
| JIA ACR Clinical Remission Based on CRP: Month 18 | 7.69 |
| JIA ACR Clinical Remission Based on CRP: Month 21 | 15.38 |
| JIA ACR Clinical Remission Based on CRP: Month 24 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 27 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 30 | 7.69 |
| JIA ACR Clinical Remission Based on CRP: Month 33 | 0 |
| JIA ACR Clinical Remission Based on CRP: Month 36 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 9 | 6.67 |
| JIA ACR Clinical Remission Based on ESR: Month 12 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 15 | 6.67 |
| JIA ACR Clinical Remission Based on ESR: Month 18 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 21 | 8.33 |
| JIA ACR Clinical Remission Based on ESR: Month 24 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 27 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 30 | 7.69 |
| JIA ACR Clinical Remission Based on ESR: Month 33 | 0 |
| JIA ACR Clinical Remission Based on ESR: Month 36 | 0 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -16.58 ± 9.48 |
| Change at Month 3 | -17.82 ± 9.53 |
| Change at Month 6 | -19.46 ± 8.28 |
| Change at Month 9 | -19.07 ± 8.53 |
| Change at Month 12 | -20.11 ± 8.96 |
| Change at Month 15 | -18.25 ± 9.63 |
| Change at Month 18 | -18.91 ± 10.42 |
| Change at Month 21 | -20.28 ± 9.46 |
| Change at Month 24 | -20.22 ± 9.32 |
| Change at Month 27 | -19.92 ± 10.94 |
| Change at Month 30 | -21.35 ± 10.96 |
| Change at Month 33 | -19.07 ± 9.74 |
| Change at Month 36 | -19.29 ± 10.49 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -16.86 ± 9.46 |
| Change at Month 3 | -18.72 ± 8.55 |
| Change at Month 6 | -19.36 ± 8.01 |
| Change at Month 9 | -19.05 ± 8.09 |
| Change at Month 12 | -19.91 ± 8.83 |
| Change at Month 15 | -18.49 ± 9.12 |
| Change at Month 18 | -19.14 ± 9.95 |
| Change at Month 21 | -20.26 ± 9.02 |
| Change at Month 24 | -20.62 ± 8.19 |
| Change at Month 27 | -20.05 ± 10.10 |
| Change at Month 30 | -22.34 ± 9.84 |
| Change at Month 33 | -18.93 ± 8.05 |
| Change at Month 36 | -17.65 ± 9.27 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -15.45 ± 8.20 |
| Change at Month 3 | -16.29 ± 8.81 |
| Change at Month 6 | -17.42 ± 8.11 |
| Change at Month 9 | -17.17 ± 8.05 |
| Change at Month 12 | -17.81 ± 8.06 |
| Change at Month 15 | -18.00 ± 8.23 |
| Change at Month 18 | -18.17 ± 8.85 |
| Change at Month 21 | -18.15 ± 8.44 |
| Change at Month 24 | -18.61 ± 8.21 |
| Change at Month 27 | -18.61 ± 7.62 |
| Change at Month 30 | -18.49 ± 8.30 |
| Change at Month 33 | -18.22 ± 7.70 |
| Change at Month 36 | -18.75 ± 8.05 |
| Change at Month 39 | -17.85 ± 8.22 |
| Change at Month 42 | -18.67 ± 7.64 |
| Change at Month 45 | -18.28 ± 7.55 |
| Change at Month 48 | -19.06 ± 7.82 |
| Change at Month 51 | -18.52 ± 7.84 |
| Change at Month 54 | -18.62 ± 6.51 |
| Change at Month 57 | -18.48 ± 7.16 |
| Change at Month 60 | -17.66 ± 6.86 |
| Change at Month 63 | -19.12 ± 8.00 |
| Change at Month 66 | -17.17 ± 7.23 |
| Change at Month 69 | -18.63 ± 7.74 |
| Change at Month 72 | -17.96 ± 8.26 |
| Change at Month 75 | -18.36 ± 7.27 |
| Change at Month 78 | -19.76 ± 7.45 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -8.80 ± 4.54 |
| Change at Month 3 | -8.49 ± 3.82 |
| Change at Month 6 | -9.61 ± 4.05 |
| Change at Month 9 | -11.23 ± 2.70 |
| Change at Month 12 | -10.16 ± 2.99 |
| Change at Month 15 | -11.12 ± 3.48 |
| Change at Month 18 | -11.78 ± 3.11 |
| Change at Month 21 | -12.30 ± 3.27 |
| Change at Month 24 | -10.75 ± 4.77 |
| Change at Month 27 | -10.91 ± 3.33 |
| Change at Month 30 | -11.46 ± 2.99 |
| Change at Month 33 | -11.42 ± 3.19 |
| Change at Month 36 | -11.27 ± 3.26 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -12.55 ± 8.09 |
| Change at Month 3 | -13.69 ± 7.65 |
| Change at Month 6 | -14.62 ± 6.43 |
| Change at Month 9 | -14.08 ± 6.48 |
| Change at Month 12 | -14.51 ± 7.48 |
| Change at Month 15 | -13.58 ± 7.56 |
| Change at Month 18 | -13.84 ± 9.87 |
| Change at Month 21 | -14.93 ± 8.50 |
| Change at Month 24 | -16.07 ± 8.55 |
| Change at Month 27 | -15.50 ± 7.95 |
| Change at Month 30 | -15.27 ± 7.53 |
| Change at Month 33 | -14.45 ± 6.96 |
| Change at Month 36 | -14.32 ± 7.11 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -16.98 ± 9.18 |
| Change at Month 3 | -18.33 ± 9.69 |
| Change at Month 6 | -20.06 ± 7.81 |
| Change at Month 9 | -19.38 ± 8.49 |
| Change at Month 12 | -20.02 ± 9.29 |
| Change at Month 15 | -17.94 ± 9.81 |
| Change at Month 18 | -18.50 ± 10.54 |
| Change at Month 21 | -20.29 ± 9.70 |
| Change at Month 24 | -20.12 ± 9.65 |
| Change at Month 27 | -19.72 ± 10.70 |
| Change at Month 30 | -20.61 ± 10.01 |
| Change at Month 33 | -18.77 ± 9.20 |
| Change at Month 36 | -19.04 ± 10.08 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -17.22 ± 9.01 |
| Change at Month 3 | -19.16 ± 8.70 |
| Change at Month 6 | -19.97 ± 7.38 |
| Change at Month 9 | -19.32 ± 7.98 |
| Change at Month 12 | -19.85 ± 8.97 |
| Change at Month 15 | -17.86 ± 9.28 |
| Change at Month 18 | -18.89 ± 10.14 |
| Change at Month 21 | -20.13 ± 9.04 |
| Change at Month 24 | -20.21 ± 8.24 |
| Change at Month 27 | -19.40 ± 9.59 |
| Change at Month 30 | -21.48 ± 8.54 |
| Change at Month 33 | -19.25 ± 7.29 |
| Change at Month 36 | -17.28 ± 9.41 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -15.30 ± 8.29 |
| Change at Month 3 | -16.39 ± 8.89 |
| Change at Month 6 | -17.39 ± 8.22 |
| Change at Month 9 | -17.25 ± 8.09 |
| Change at Month 12 | -17.73 ± 8.25 |
| Change at Month 15 | -18.00 ± 7.96 |
| Change at Month 18 | -18.00 ± 8.50 |
| Change at Month 21 | -18.18 ± 8.35 |
| Change at Month 24 | -18.41 ± 8.03 |
| Change at Month 27 | -18.84 ± 7.61 |
| Change at Month 30 | -18.09 ± 8.21 |
| Change at Month 33 | -17.95 ± 7.44 |
| Change at Month 36 | -18.46 ± 7.99 |
| Change at Month 39 | -17.34 ± 8.17 |
| Change at Month 42 | -18.18 ± 7.50 |
| Change at Month 45 | -18.36 ± 7.66 |
| Change at Month 48 | -18.72 ± 7.65 |
| Change at Month 51 | -18.00 ± 7.49 |
| Change at Month 54 | -18.91 ± 6.73 |
| Change at Month 57 | -17.85 ± 6.89 |
| Change at Month 60 | -17.16 ± 7.44 |
| Change at Month 63 | -17.97 ± 7.22 |
| Change at Month 66 | -16.95 ± 7.62 |
| Change at Month 69 | -17.83 ± 7.54 |
| Change at Month 72 | -17.35 ± 7.74 |
| Change at Month 75 | -17.61 ± 8.02 |
| Change at Month 78 | -18.45 ± 7.83 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -8.95 ± 4.93 |
| Change at Month 3 | -8.76 ± 4.21 |
| Change at Month 6 | -10.11 ± 4.13 |
| Change at Month 9 | -11.51 ± 2.76 |
| Change at Month 12 | -10.30 ± 3.20 |
| Change at Month 15 | -11.48 ± 3.48 |
| Change at Month 18 | -12.20 ± 3.34 |
| Change at Month 21 | -12.63 ± 3.40 |
| Change at Month 24 | -10.95 ± 4.95 |
| Change at Month 27 | -9.92 ± 4.35 |
| Change at Month 30 | -11.71 ± 3.16 |
| Change at Month 33 | -11.65 ± 3.42 |
| Change at Month 36 | -11.49 ± 3.56 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 1 | -13.73 ± 7.09 |
| Change at Month 3 | -13.96 ± 7.11 |
| Change at Month 6 | -15.02 ± 5.44 |
| Change at Month 9 | -14.58 ± 5.76 |
| Change at Month 12 | -14.90 ± 6.69 |
| Change at Month 15 | -14.25 ± 6.89 |
| Change at Month 18 | -14.86 ± 8.09 |
| Change at Month 21 | -15.59 ± 8.14 |
| Change at Month 24 | -15.48 ± 7.94 |
| Change at Month 27 | -16.02 ± 7.21 |
| Change at Month 30 | -15.08 ± 7.61 |
| Change at Month 33 | -14.58 ± 6.03 |
| Change at Month 36 | -14.00 ± 6.84 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Minimum Disease Activity: Month 1 | 43.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 3 | 55.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 6 | 56.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 9 | 55.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 12 | 54.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 15 | 48.9 |
| JADAS-27 CRP Minimum Disease Activity: Month 18 | 50.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 21 | 53.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 24 | 51.9 |
| JADAS-27 CRP Minimum Disease Activity: Month 27 | 56.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 30 | 58.8 |
| JADAS-27 CRP Minimum Disease Activity: Month 33 | 54.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 36 | 66.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 1 | 47.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 3 | 54.9 |
| JADAS-27 ESR Minimum Disease Activity: Month 6 | 59.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 9 | 53.9 |
| JADAS-27 ESR Minimum Disease Activity: Month 12 | 51.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 15 | 46.8 |
| JADAS-27 ESR Minimum Disease Activity: Month 18 | 47.4 |
| JADAS-27 ESR Minimum Disease Activity: Month 21 | 51.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 24 | 40.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 27 | 62.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 30 | 52.9 |
| JADAS-27 ESR Minimum Disease Activity: Month 33 | 41.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 36 | 44.4 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Minimum Disease Activity: Month 1 | 43.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 3 | 57.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 6 | 55.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 9 | 55.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 12 | 51.9 |
| JADAS-27 CRP Minimum Disease Activity: Month 15 | 48.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 18 | 53.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 21 | 54.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 24 | 57.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 27 | 55.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 30 | 69.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 33 | 71.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 36 | 80.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 1 | 48.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 3 | 56.8 |
| JADAS-27 ESR Minimum Disease Activity: Month 6 | 58.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 9 | 55.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 12 | 51.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 15 | 46.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 18 | 51.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 21 | 52.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 24 | 47.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 27 | 63.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 30 | 61.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 33 | 62.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 36 | 40.0 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Minimum Disease Activity: Month 1 | 52.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 3 | 58.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 6 | 61.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 9 | 58.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 12 | 66.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 15 | 66.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 18 | 70.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 21 | 67.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 24 | 64.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 27 | 70.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 30 | 67.9 |
| JADAS-27 CRP Minimum Disease Activity: Month 33 | 70.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 36 | 71.8 |
| JADAS-27 CRP Minimum Disease Activity: Month 39 | 68.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 42 | 75.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 45 | 70.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 48 | 74.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 51 | 74.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 54 | 71.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 57 | 72.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 60 | 65.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 63 | 72.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 66 | 72.1 |
| JADAS-27 CRP Minimum Disease Activity: Month 69 | 74.4 |
| JADAS-27 CRP Minimum Disease Activity: Month 72 | 69.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 75 | 73.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 78 | 82.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 1 | 52.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 3 | 54.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 6 | 58.8 |
| JADAS-27 ESR Minimum Disease Activity: Month 9 | 55.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 12 | 61.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 15 | 63.9 |
| JADAS-27 ESR Minimum Disease Activity: Month 18 | 68.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 21 | 61.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 24 | 61.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 27 | 69.4 |
| JADAS-27 ESR Minimum Disease Activity: Month 30 | 64.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 33 | 64.8 |
| JADAS-27 ESR Minimum Disease Activity: Month 36 | 69.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 39 | 65.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 42 | 69.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 45 | 69.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 48 | 69.9 |
| JADAS-27 ESR Minimum Disease Activity: Month 51 | 73.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 54 | 67.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 57 | 72.4 |
| JADAS-27 ESR Minimum Disease Activity: Month 60 | 63.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 63 | 77.8 |
| JADAS-27 ESR Minimum Disease Activity: Month 66 | 74.4 |
| JADAS-27 ESR Minimum Disease Activity: Month 69 | 77.3 |
| JADAS-27 ESR Minimum Disease Activity: Month 72 | 72.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 75 | 72.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 78 | 81.3 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Minimum Disease Activity: Month 1 | 54.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 3 | 35.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 6 | 43.8 |
| JADAS-27 CRP Minimum Disease Activity: Month 9 | 64.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 12 | 46.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 15 | 69.2 |
| JADAS-27 CRP Minimum Disease Activity: Month 18 | 50.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 21 | 72.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 24 | 63.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 27 | 63.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 30 | 70.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 33 | 63.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 36 | 66.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 1 | 54.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 3 | 35.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 6 | 37.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 9 | 57.1 |
| JADAS-27 ESR Minimum Disease Activity: Month 12 | 46.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 15 | 69.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 18 | 50.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 21 | 66.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 24 | 63.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 27 | 60.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 30 | 60.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 33 | 63.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 36 | 66.7 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Minimum Disease Activity: Month 1 | 66.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 3 | 64.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 6 | 66.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 9 | 60.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 12 | 80.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 15 | 66.7 |
| JADAS-27 CRP Minimum Disease Activity: Month 18 | 61.5 |
| JADAS-27 CRP Minimum Disease Activity: Month 21 | 58.3 |
| JADAS-27 CRP Minimum Disease Activity: Month 24 | 81.8 |
| JADAS-27 CRP Minimum Disease Activity: Month 27 | 81.8 |
| JADAS-27 CRP Minimum Disease Activity: Month 30 | 75.0 |
| JADAS-27 CRP Minimum Disease Activity: Month 33 | 63.6 |
| JADAS-27 CRP Minimum Disease Activity: Month 36 | 55.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 1 | 71.4 |
| JADAS-27 ESR Minimum Disease Activity: Month 3 | 69.2 |
| JADAS-27 ESR Minimum Disease Activity: Month 6 | 66.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 9 | 60.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 12 | 80.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 15 | 66.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 18 | 61.5 |
| JADAS-27 ESR Minimum Disease Activity: Month 21 | 63.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 24 | 80.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 27 | 91.7 |
| JADAS-27 ESR Minimum Disease Activity: Month 30 | 75.0 |
| JADAS-27 ESR Minimum Disease Activity: Month 33 | 63.6 |
| JADAS-27 ESR Minimum Disease Activity: Month 36 | 55.6 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Inactive Disease Activity: Month 1 | 24.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 3 | 30.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 6 | 30.8 |
| JADAS-27 CRP Inactive Disease Activity: Month 9 | 28.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 12 | 28.8 |
| JADAS-27 CRP Inactive Disease Activity: Month 15 | 29.8 |
| JADAS-27 CRP Inactive Disease Activity: Month 18 | 39.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 21 | 32.1 |
| JADAS-27 CRP Inactive Disease Activity: Month 24 | 33.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 27 | 30.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 30 | 41.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 33 | 27.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 36 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 1 | 27.4 |
| JADAS-27 ESR Inactive Disease Activity: Month 3 | 37.8 |
| JADAS-27 ESR Inactive Disease Activity: Month 6 | 34.6 |
| JADAS-27 ESR Inactive Disease Activity: Month 9 | 31.6 |
| JADAS-27 ESR Inactive Disease Activity: Month 12 | 24.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 15 | 29.8 |
| JADAS-27 ESR Inactive Disease Activity: Month 18 | 39.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 21 | 34.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 24 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 27 | 37.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 30 | 35.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 33 | 25.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 36 | 22.2 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Inactive Disease Activity: Month 1 | 24.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 3 | 31.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 6 | 30.6 |
| JADAS-27 CRP Inactive Disease Activity: Month 9 | 27.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 12 | 25.0 |
| JADAS-27 CRP Inactive Disease Activity: Month 15 | 33.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 18 | 40.6 |
| JADAS-27 CRP Inactive Disease Activity: Month 21 | 36.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 24 | 38.1 |
| JADAS-27 CRP Inactive Disease Activity: Month 27 | 38.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 30 | 46.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 33 | 42.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 36 | 60.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 1 | 27.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 3 | 39.2 |
| JADAS-27 ESR Inactive Disease Activity: Month 6 | 34.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 9 | 31.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 12 | 23.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 15 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 18 | 41.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 21 | 39.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 24 | 38.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 27 | 42.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 30 | 46.2 |
| JADAS-27 ESR Inactive Disease Activity: Month 33 | 37.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 36 | 40.0 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Inactive Disease Activity: Month 1 | 28.8 |
| JADAS-27 CRP Inactive Disease Activity: Month 3 | 35.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 6 | 36.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 9 | 38.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 12 | 36.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 15 | 37.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 18 | 40.0 |
| JADAS-27 CRP Inactive Disease Activity: Month 21 | 37.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 24 | 38.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 27 | 43.0 |
| JADAS-27 CRP Inactive Disease Activity: Month 30 | 47.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 33 | 43.8 |
| JADAS-27 CRP Inactive Disease Activity: Month 36 | 45.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 39 | 41.1 |
| JADAS-27 CRP Inactive Disease Activity: Month 42 | 47.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 45 | 51.1 |
| JADAS-27 CRP Inactive Disease Activity: Month 48 | 43.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 51 | 45.1 |
| JADAS-27 CRP Inactive Disease Activity: Month 54 | 46.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 57 | 48.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 60 | 46.9 |
| JADAS-27 CRP Inactive Disease Activity: Month 63 | 54.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 66 | 44.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 69 | 51.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 72 | 52.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 75 | 48.6 |
| JADAS-27 CRP Inactive Disease Activity: Month 78 | 50.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 1 | 28.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 3 | 34.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 6 | 37.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 9 | 36.4 |
| JADAS-27 ESR Inactive Disease Activity: Month 12 | 33.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 15 | 40.6 |
| JADAS-27 ESR Inactive Disease Activity: Month 18 | 39.2 |
| JADAS-27 ESR Inactive Disease Activity: Month 21 | 37.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 24 | 38.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 27 | 47.2 |
| JADAS-27 ESR Inactive Disease Activity: Month 30 | 45.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 33 | 43.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 36 | 43.8 |
| JADAS-27 ESR Inactive Disease Activity: Month 39 | 41.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 42 | 45.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 45 | 48.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 48 | 41.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 51 | 47.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 54 | 44.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 57 | 44.8 |
| JADAS-27 ESR Inactive Disease Activity: Month 60 | 42.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 63 | 57.8 |
| JADAS-27 ESR Inactive Disease Activity: Month 66 | 41.9 |
| JADAS-27 ESR Inactive Disease Activity: Month 69 | 50.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 72 | 51.2 |
| JADAS-27 ESR Inactive Disease Activity: Month 75 | 50.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 78 | 53.1 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Inactive Disease Activity: Month 1 | 36.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 3 | 14.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 6 | 31.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 9 | 28.6 |
| JADAS-27 CRP Inactive Disease Activity: Month 12 | 40.0 |
| JADAS-27 CRP Inactive Disease Activity: Month 15 | 15.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 18 | 33.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 21 | 36.4 |
| JADAS-27 CRP Inactive Disease Activity: Month 24 | 27.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 27 | 18.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 30 | 20.0 |
| JADAS-27 CRP Inactive Disease Activity: Month 33 | 27.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 36 | 16.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 1 | 27.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 3 | 14.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 6 | 25.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 9 | 21.4 |
| JADAS-27 ESR Inactive Disease Activity: Month 12 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 15 | 23.1 |
| JADAS-27 ESR Inactive Disease Activity: Month 18 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 21 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 24 | 36.4 |
| JADAS-27 ESR Inactive Disease Activity: Month 27 | 10.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 30 | 20.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 33 | 27.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 36 | 16.7 |
JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| JADAS-27 CRP Inactive Disease Activity: Month 1 | 26.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 3 | 35.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 6 | 53.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 9 | 26.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 12 | 53.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 15 | 26.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 18 | 46.2 |
| JADAS-27 CRP Inactive Disease Activity: Month 21 | 41.7 |
| JADAS-27 CRP Inactive Disease Activity: Month 24 | 45.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 27 | 45.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 30 | 58.3 |
| JADAS-27 CRP Inactive Disease Activity: Month 33 | 54.5 |
| JADAS-27 CRP Inactive Disease Activity: Month 36 | 33.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 1 | 35.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 3 | 38.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 6 | 46.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 9 | 26.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 12 | 40.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 15 | 26.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 18 | 38.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 21 | 45.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 24 | 40.0 |
| JADAS-27 ESR Inactive Disease Activity: Month 27 | 41.7 |
| JADAS-27 ESR Inactive Disease Activity: Month 30 | 58.3 |
| JADAS-27 ESR Inactive Disease Activity: Month 33 | 45.5 |
| JADAS-27 ESR Inactive Disease Activity: Month 36 | 33.3 |
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, methotrexate (MTX)/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Oral corticosteroids: Eligibility of tapering | 12.05 |
| Oral corticosteroids: Partial tapering success among all | 3.61 |
| Oral corticosteroids: Complete tapering success among all | 8.43 |
| Oral corticosteroids: Partial tapering success among eligible | 30.00 |
| Oral corticosteroids: Complete tapering success among eligible | 70.00 |
| Methotrexate/Leflunomide: Eligibility of tapering | 3.61 |
| Methotrexate/Leflunomide: Partial tapering success among all | 0 |
| Methotrexate/Leflunomide: Complete tapering success among all | 1.20 |
| Methotrexate/Leflunomide: Partial tapering success among eligible | 0 |
| Methotrexate/Leflunomide: Complete tapering success among eligible | 33.33 |
| Tofacitinib: Eligibility of tapering | 3.61 |
| Tofacitinib: Partial tapering success among all | 0 |
| Tofacitinib: Complete tapering success among all | 3.61 |
| Tofacitinib: Partial tapering success among eligible | 0 |
| Tofacitinib: Complete tapering success among eligible | 100 |
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Oral corticosteroids: Eligibility of tapering | 10.39 |
| Oral corticosteroids: Partial tapering success among all | 3.90 |
| Oral corticosteroids: Complete tapering success among all | 6.49 |
| Oral corticosteroids: Partial tapering success among eligible | 37.50 |
| Oral corticosteroids: Complete tapering success among eligible | 62.50 |
| Methotrexate/Leflunomide: Eligibility of tapering | 3.90 |
| Methotrexate/Leflunomide: Partial tapering success among all | 0 |
| Methotrexate/Leflunomide: Complete tapering success among all | 1.30 |
| Methotrexate/Leflunomide: Partial tapering success among eligible | 0 |
| Methotrexate/Leflunomide: Complete tapering success among eligible | 33.33 |
| Tofacitinib: Eligibility of tapering | 3.90 |
| Tofacitinib: Partial tapering success among all | 0 |
| Tofacitinib: Complete tapering success among all | 3.90 |
| Tofacitinib: Partial tapering success among eligible | 0 |
| Tofacitinib: Complete tapering success among eligible | 100 |
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Oral corticosteroids: Eligibility of tapering | 8.90 |
| Oral corticosteroids: Partial tapering success among all | 2.05 |
| Oral corticosteroids: Complete tapering success among all | 6.85 |
| Oral corticosteroids: Partial tapering success among eligible | 23.08 |
| Oral corticosteroids: Complete tapering success among eligible | 76.92 |
| Methotrexate/Leflunomide: Eligibility of tapering | 12.93 |
| Methotrexate/Leflunomide: Partial tapering success among all | 2.04 |
| Methotrexate/Leflunomide: Complete tapering success among all | 10.20 |
| Methotrexate/Leflunomide: Partial tapering success among eligible | 15.79 |
| Methotrexate/Leflunomide: Complete tapering success among eligible | 78.95 |
| Tofacitinib: Eligibility of tapering | 4.76 |
| Tofacitinib: Partial tapering success among all | 2.04 |
| Tofacitinib: Complete tapering success among all | 1.36 |
| Tofacitinib: Partial tapering success among eligible | 42.86 |
| Tofacitinib: Complete tapering success among eligible | 28.57 |
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Oral corticosteroids: Eligibility of tapering | 0 |
| Oral corticosteroids: Partial tapering success among all | 0 |
| Oral corticosteroids: Complete tapering success among all | 0 |
| Methotrexate/Leflunomide: Eligibility of tapering | 7.69 |
| Methotrexate/Leflunomide: Partial tapering success among all | 0 |
| Methotrexate/Leflunomide: Complete tapering success among all | 7.69 |
| Methotrexate/Leflunomide: Partial tapering success among eligible | 0 |
| Methotrexate/Leflunomide: Complete tapering success among eligible | 100 |
| Tofacitinib: Eligibility of tapering | 7.69 |
| Tofacitinib: Partial tapering success among all | 7.69 |
| Tofacitinib: Complete tapering success among all | 0 |
| Tofacitinib: Partial tapering success among eligible | 100 |
| Tofacitinib: Complete tapering success among eligible | 0 |
Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Oral corticosteroids: Eligibility of tapering | 6.67 |
| Oral corticosteroids: Partial tapering success among all | 0 |
| Oral corticosteroids: Complete tapering success among all | 6.67 |
| Oral corticosteroids: Partial tapering success among eligible | 0 |
| Oral corticosteroids: Complete tapering success among eligible | 100 |
| Methotrexate/Leflunomide: Eligibility of tapering | 13.33 |
| Methotrexate/Leflunomide: Partial tapering success among all | 0 |
| Methotrexate/Leflunomide: Complete tapering success among all | 13.33 |
| Methotrexate/Leflunomide: Partial tapering success among eligible | 0 |
| Methotrexate/Leflunomide: Complete tapering success among eligible | 100 |
| Tofacitinib: Eligibility of tapering | 6.67 |
| Tofacitinib: Partial tapering success among all | 0 |
| Tofacitinib: Complete tapering success among all | 6.67 |
| Tofacitinib: Partial tapering success among eligible | 0 |
| Tofacitinib: Complete tapering success among eligible | 100 |
Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| At Month 1 | 95.35 |
| At Month 3 | 97.59 |
| At Month 6 | 100 |
| At Month 9 | 97.44 |
| At Month 12 | 100 |
| At Month 15 | 97.96 |
| At Month 18 | 94.87 |
| At Month 21 | 100 |
| At Month 24 | 100 |
| At Month 27 | 100 |
| At Month 30 | 100 |
| At Month 33 | 100 |
| At Month 36 | 100 |
Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.
| Percentage of participants | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| At Month 1 | 94.81 |
| At Month 3 | 97.30 |
| At Month 6 | 100 |
| At Month 9 | 97.14 |
| At Month 12 | 100 |
| At Month 15 | 97.56 |
| At Month 18 | 93.75 |
| At Month 21 | 100 |
| At Month 24 | 100 |
| At Month 27 | 100 |
| At Month 30 | 100 |
| At Month 33 | 100 |
| At Month 36 | 100 |
Tender entheseal assessment was performed by the investigator as 'Yes' or 'No'. 'Yes' indicated the presence of tenderness upon firm palpation over the specified enthesis and 'No' indicated the absence of tenderness upon firm palpation over the indicated enthesis. A total of 16 entheseal sites were assessed and the number of tender sites was counted. The score ranges from 0 to 16, where 0 represents the best possible outcome (no tenderness) and 16 represents the worst possible outcome (maximum tenderness).
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | -4.47 ± 4.82 |
| Change at Month 6 | -4.83 ± 5.08 |
| Change at Month 12 | -4.33 ± 4.70 |
| Change at Month 18 | -5.08 ± 5.16 |
| Change at Month 24 | -5.33 ± 4.38 |
| Change at Month 30 | -4.75 ± 5.50 |
| Change at Month 36 | -4.83 ± 4.78 |
Modified Schober's test was performed at the study visits only in participants with enthesitis-related arthritis. With the participant standing erect and with feet together, a line joining the posterior superior iliac spines (the dimples of Venus) was used as a landmark for the lumbosacral junction. A mark was made 5 centimeters (cm) below and 10 cm above the lumbosacral junction. With the participant in maximum forward flexion with the knees straight, the investigator measures the distance between the two marks in centimeters. The full measurement between the two lines was recorded to the nearest tenth of a centimeter (e.g., 15.2 cm) on the appropriate CRF.
| Centimeters | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | 0.37 ± 1.14 |
| Change at Month 6 | 0.34 ± 1.15 |
| Change at Month 12 | 0.20 ± 1.21 |
| Change at Month 18 | 0.29 ± 1.30 |
| Change at Month 24 | 0.09 ± 1.32 |
| Change at Month 30 | -0.87 ± 2.29 |
| Change at Month 36 | 0.13 ± 1.82 |
Severity of overall back pain (at any time) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | -3.18 ± 2.57 |
| Change at Month 6 | -2.78 ± 2.29 |
| Change at Month 12 | -3.57 ± 2.57 |
| Change at Month 18 | -3.83 ± 2.45 |
| Change at Month 24 | -3.70 ± 2.82 |
| Change at Month 30 | -3.11 ± 3.29 |
| Change at Month 36 | -3.46 ± 3.14 |
Severity of nocturnal back pain (at night) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | -2.16 ± 2.56 |
| Change at Month 6 | -1.78 ± 2.62 |
| Change at Month 12 | -2.67 ± 2.18 |
| Change at Month 18 | -3.04 ± 2.52 |
| Change at Month 24 | -3.10 ± 2.53 |
| Change at Month 30 | -2.44 ± 2.67 |
| Change at Month 36 | -2.58 ± 3.11 |
BSA was measured as the percentage of BSA affected by psoriasis using the palm method; the participants palm was used for the calculation. One of the participant's palm to proximal interphalangeal (PIP) and thumb equals to 1% of BSA. Regions of the body included along with percentage of BSA: 1) head and neck = 10% (10 palms); 2) upper extremities = 20% (20 palms); 3) trunk (axillae and groin) = 30% (30 palms) and 4) lower extremities (buttocks) = 40% (40 palms).Total BSA was sum of all regions ranged from 0% to 100% (100 palms). The physician assessed the total BSA affected by psoriasis using the addition of the individual regions.
| Percentage of BSA | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | -1.81 ± 3.66 |
| Change at Month 6 | -2.03 ± 3.96 |
| Change at Month 12 | -1.89 ± 3.93 |
| Change at Month 18 | -1.73 ± 4.86 |
| Change at Month 24 | -2.00 ± 5.42 |
| Change at Month 30 | -1.77 ± 4.14 |
| Change at Month 36 | -1.53 ± 2.51 |
PGA was used to determine participant's overall psoriasis lesions at a given time point. Overall lesions were graded for induration, erythema, and scaling based upon scales. Induration scale ranged from: 0 (no evidence of plaque elevation) to 5 (severe plaque elevation or more); erythema scale ranged from: 0 (no evidence of erythema, hyper pigmentation may be present) to 5 (dusky to deep red coloration); scaling scale ranged from: 0 (no evidence of scaling) to 5 (severe; very thick tenacious scale predominates). Total PGA score was calculated based on sum of 3 scales divided by 3 to obtain final PGA, ranging from 0 (no evidence) to 5 (maximum severity); higher scores indicated more severity of psoriasis.
| Score on a scale | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Change at Month 3 | -0.56 ± 1.26 |
| Change at Month 6 | -0.60 ± 1.24 |
| Change at Month 12 | -0.71 ± 1.20 |
| Change at Month 18 | -0.67 ± 1.30 |
| Change at Month 24 | -0.64 ± 1.50 |
| Change at Month 30 | -0.69 ± 1.03 |
| Change at Month 36 | -0.44 ± 1.01 |
Collected over From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID (Open-label) | 2/302 (0.7%) | 48/302 (15.9%) | 242/302 (80.1%) |
| Event | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Still's diseaseMusculoskeletal and connective tissue disorders | 8/302 |
| Suicidal ideationPsychiatric disorders | 5/302 |
| Herpes zosterInfections and infestations | 4/302 |
| PyrexiaGeneral disorders | 3/302 |
| Appendicitis noninfectiveGastrointestinal disorders | 2/302 |
| Haemophagocytic lymphohistiocytosisImmune system disorders | 2/302 |
| PneumoniaInfections and infestations | 2/302 |
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 2/302 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/302 |
| Suicide attemptPsychiatric disorders | 2/302 |
| Event | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 66/302 |
| NasopharyngitisInfections and infestations | 40/302 |
| Urinary tract infectionInfections and infestations | 29/302 |
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 29/302 |
| Viral infectionInfections and infestations | 27/302 |
| PyrexiaGeneral disorders | 25/302 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 25/302 |
| Abdominal painGastrointestinal disorders | 23/302 |
| HeadacheNervous system disorders | 22/302 |
| VomitingGastrointestinal disorders | 20/302 |
| Age, Continuous(Years) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Mean | 11.86 ± 4.38 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| Female | 202 |
| Male | 100 |
| Race (NIH/OMB)(Participants) | Tofacitinib 5 mg BID (Open-label) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 37 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 11 |
| White | 229 |
| More than one race | 0 |
| Unknown or Not Reported | 25 |
Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2013 to primary completion in Feb 2025, 142 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib